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ACT activated clotting time
ANH acute normovolemic hemodilution
ANOVA analysis of variance
APTT activated partial thromboplastin time
CABG coronary artery bypass
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DDAVP desamino-8-d-arginine vasopressin, desmopressin
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HIV human immunodeficiency virus
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PT prothrombin time
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TBV estimated total blood volume
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TRALI transfusion-related acute lung injury
TURP transurethral resection of the prostate
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ABSTRACT
Evidence of large variation in the surgical transfusion policies between countries and
hospitals suggests that practice may often be less than optimal. Comparative bench-
marking studies are needed to give a basis for interventions to improve practice. The
aim of the present series of studies was to examine the transfusion policies in common
elective surgical procedures in Finnish hospitals, and to identify areas of practice that
would need improvement.
In a retrospective multicenter survey, the transfusions in 2308 elective surgical pro-
cedures performed in 16 Finnish hospitals in 1993–1994 were reviewed. The operations
included primary coronary artery bypass (CABG, 804 patients), total hip replacement
(THR, 764 patients) and total knee replacement (TKR, 397 patients), and transurethral
resection of the prostate (TURP, 343 patients). To seek methods to optimize the
transfusion practices, an algorithm with timely laboratory monitoring to guide the
management of bleeding after cardiac surgery was designed. Its effect on transfusions
and hemostatic outcome was prospectively studied in 58 cardiac patients randomly
assigned to receive either algorithm-based or empirical therapy. In addition, a register-
based population study of transfusions given in all 2363 CABG operations performed
in 1997–1999 in a university hospital was carried out to evaluate the development of
transfusion trends in CABG.
According to the survey, the overall proportions of patients receiving allogeneic red cell
(RBC) transfusions were 87% in CABG, 92% in THR, 84% in TKR, and 18% in
TURP. However, significant interhospital variation in the RBC transfusion rates was
detected: from 53 to 99% in CABG, from 79 to 100% in THR, from 57 to 98% in
TKR and from 7 to 31% in TURP. The use of hemostatic blood components in CABG
was also variable and empirically guided. The differences were not due to diverse patient
populations: after the effect of patient characteristics and surgical variables was
excluded, the mean number of blood components transfused per patient in equal
operations varied as much as six-fold between hospitals. The transfusion triggers were
also evaluated in the survey: in orthopedics, most patients who lost 20% or less of their
blood volume during hospitalization were transfused with RBCs. In all operations, the
median postoperative hemoglobin transfusion triggers approximated 100 g/l. The
algorithm-based therapy increased hemostatic interventions in bleeding cardiac patients
without benefiting the hemostatic outcome. A decrease in the allogeneic transfusion
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rate in CABG operations in a university hospital from 76% in 1993–1994 to 48% in
1997–1999 was detected in the register-based study.
The initial transfusion rates in Finnish hospitals were high, and the transfusion triggers
seemed liberal compared to international recommendations. In addition, the transfusion
practices proved variable between hospitals, and were largely determined by local
transfusion criteria. However, during the course of the study, a substantial decrease in
transfusions in CABG operations was detected in a university hospital. The transfusion
algorithm did not optimize the treatment of bleeding after cardiac surgery, but warrants
further development. The data automatically stored in hospital registers provides a good
means for future auditing of surgical transfusion practices.
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INTRODUCTION
Since the foundation of the Finnish Red Cross Blood Transfusion Service in 1948,
transfusion services in Finland have been organized on a voluntary and nonremunerated
basis. Every blood donor expects that blood products are used for the right indications
and for the benefit of a patient needing the donor’s gift. Most blood products are
transfused to surgical patients, either to replace acute blood loss or to correct post-
operative anemia, which, if severe, could compromise the patient’s recovery. Conse-
quently, the majority of the blood products may be transfused on the order of anesthesi-
ologists, who, thereby, form one of the key groups ensuring that donor blood is used
optimally for patient care.
Although the risks of blood transfusion have substantially diminished in recent years,
the avoidance of inappropriate transfusions is still of utmost importance. Like all
clinical decisions, transfusion of blood components in association with surgery is based
on careful consideration of the benefits and risks in the case of each individual patient.
In addition, thought should be given to the use of applicable blood conservation meth-
ods such as hemostatic agents and autologous blood.
However, scientific evidence concerning the risks of anemia and the benefits of blood
component transfusion in surgical patients is still scarce, and the physicians making
transfusion decisions are faced with conflicting information. To guide clinical decision-
making, several consensus conferences formulating transfusion guidelines based on
available data have been organized. However, the opinions of these experts have been
poorly applicable in clinical practice. Local clinical tradition and training seem to play a
major role in each hospital’s transfusion practices, and implementing transfusion
guidelines remains a challenge. Furthermore, clinical situations are dynamic and the
patients variable, which has led to inconstant transfusion practices.
The variable surgical transfusion practices were demonstrated by the SANGUIS-study
conducted in 43 hospitals in ten EU countries (Sirchia et al. 1994). In this study, hemo-
therapy associated with six standard surgical operations was carefully recorded, and then
correlated with a number of clinical parameters of the patients. After the effect of
patient characteristics and surgical variables was excluded, marked differences persisted
between countries and hospitals in transfusion practices in each of the six procedures. In
fact, the chance of being transfused in equivalent surgical procedures varied from 0% to
100% between EU hospitals.
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The need for more rational hemotherapy thus varies between different countries and
hospitals within a same country. Therefore, comparative benchmarking studies on
transfusion policies give a sound basis for interventions to improve practice. This study
aimed to clarify the transfusion practices in elective surgical operations in Finnish
hospitals, and to identify areas of practice that would need improvement.
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REVIEW OF THE LITERATURE
1. Clinical use of blood components
1.1. Trends in blood component usage
1.1.1. Red cells
In the beginning of the 1990s, the usage of allogeneic red cells (RBC) (Table 1) in
Finland grew annually by at least 5%. The demand was largest in 1996, when 363 349
units were collected, and 63 units of RBC were distributed per 1000 inhabitants. In the
last few years, there has been a leveling off and slight decline in the use, and currently,
approximately 56 units of RBCs are distributed annually per 1000 inhabitants (Finnish
Red Cross Blood Transfusion Service, Annual reports 1990–2000). In Finland, the
availability of donor blood has not been a limiting factor in the use of RBCs.
In many other western European countries, however, the demand for RBCs seems to be
smaller. Most countries transfuse an average of 30 to 40 units of RBCs per 1000
inhabitants, and in only a few countries such as Denmark, Sweden, Scotland, and
Belgium, the annual RBC usage is over 50 units per 1000 inhabitants (Gunnar Myllylä,
unpublished data). In the USA, the average annual use of RBCs is approximately 40
units per 1000 inhabitants (Vamvakas and Taswell 1994).
Some attributes of RBC transfusion recipients which can be utilized in the planning
and predicting of local blood needs have been defined in the literature. The majority of
RBC units are transfused to surgical patients, cardiac and orthopedic surgery being the
fields of surgery associated with the most RBC transfusions (Vamvakas and Taswell
1994; Chiavetta et al. 1996). Cook and Epps (1991) define the 25 most frequent
diagnoses associated with RBC transfusions; the five main categories include diseases of
the circulatory, digestive, and musculoskeletal systems, neoplasms, and injuries. Elderly
patients may be an increasingly significant group of transfusion recipients. According to
US data from 1989–1992, over half of all RBC units (53%) were transfused to patients
over 65 years of age, and the probability of transfusion in those over 65 has been 20-
fold higher than in those less than 40 (Vamvakas and Taswell 1994).
In Finland, cardiac surgery and orthopedics are the fastest growing fields of surgery.
During the 1990s, the number of cardiac surgical procedures has nearly doubled, and
the number of orthopedic procedures has grown by 50% (http://www.stakes.fi/
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stakestieto/hoitojaksot.htm; Rasilainen and Salmela 1995). From 1990 to 1999, the
proportion of inhabitants aged over 65 years in Finland has increased from 13.5% to
20.2% (Tilastokeskus 2000). No complete data concerning the number of surgical
procedures performed annually in industrialized countries exists. However, the number
of common surgical procedures such as coronary artery bypass (CABG) or total hip
replacements performed annually in Finland is comparable with the rates of other
industrialized countries (Madsen et al. 1994; Ghosh and Unger 2000; OECD 2000).
Although the growth of RBC usage may be explained by the demographic changes and
increasing number of surgical procedures in Finland, the large number of RBC units
transfused annually per inhabitant is not completely understood.
Table 1. Basic blood components used for surgical patients in Finland.
PRODUCT UNIT /
PRODUCT DEFINITION COMPOSITION INDICATION
Whole blood Blood collected from a 450±50 ml of blood + CPD Source material for blood
(WB) healthy blood donor  preservative product preparation, rarely
transfused into patient
Red cells Blood component obtained Volume 280±50 ml Maintenance of oxygen-
  (RBC) by removing plasma and BC · Hct 0.50-0.70 carrying capacity of the
layer from a WB unit and · Hb >45g blood
adding SAGM solution
Fresh-frozen Plasma separated from a unit Volume 265±50 ml Correction of coagulation
plasma of WB, quickly frozen, and · contains ≥70% of original deficit particularly in
(FFP) stored at <30°C labile coagulation factors situations with multiple
(FV and FVIII:C) besides coagulation defects and
stabile plasma proteins bleeding tendency
Platelets Blood platelets separated Platelet unit = platelets separated Correction or prevention of
from a unit of fresh WB from one unit of WB, on average bleeding tendency due to
and suspended in platelet 70 x 109 platelets platelet deficiency or
additive solution · for practical purposes four dysfunction
such units pooled as a
therapeutic unit
BC = buffy coat (white cell/platelet layer); CPD = citrate-phosphate-dextrose; Hb = hemoglobin; Hct = hematocrit;
SAGM = saline-adenine-glucose-mannitol. Modified from Council of Europe Recommendation No. R (95) 15,
2001.
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1.1.2. Platelets and fresh-frozen plasma
Clinical use of platelets (Table 1) has increased greatly in industrialized countries during
the last 15 years (Gunnar Myllylä, unpublished data). However, this trend does not
indicate changes in surgical transfusion therapy, because not more than 15% of the
platelet units are transfused in association with surgery (Simon 1991). Indications for
platelet transfusions in surgical patients have remained largely the same for a long time,
except in cardiac surgery, in which the once widespread prophylactic use of platelets has
been abandoned (Simpson 1988).
Development of the clinical use of fresh-frozen plasma (FFP) (Table 1) has varied in
different countries, and largely reflects changes in the treatment of acute blood loss
(Hiippala 1998). In many countries, a substantial part of FFP may have been used
inappropriately as a volume expander. Thus, the use of FFP has varied between 5 and
30 units of FFP per 1000 inhabitants in industrialized countries during the 1990’s
(Gunnar Myllylä, unpublished data). In Finland, FFP usage has always been compara-
tively low, but has increased from 5 to 7 units per 1000 inhabitants during the 1990’s
(Finnish Red Cross Blood Transfusion Service, Annual reports 1990–2000).
1.2. Risks of blood transfusion
All medical therapies incur  both benefits and risks, which must be carefully weighed
when planning the care of an individual patient. The adverse effects associated with
blood transfusions are shown in Table 2.
Table 2. Adverse effects of blood transfusion
Immune complications
Acute hemolytic transfusion reaction
Delayed hemolytic transfusion reaction
Transfusion-related acute lung injury
Post-transfusion purpura
Transfusion-associated graft-versus-host disease
Anaphylactic reactions
Transfusion-transmitted infections
Transfusion-associated immunomodulatory effects
The real risk associated with blood transfusion has often remained unclear to both the
physicians and the patients. Hemovigilance organizations recently established in some
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European countries offer a significant contribution to the assessment of transfusion
risks. The hemovigilance concept is described in detail in section 5.1. on page 38.
A summary of adverse event reports submitted to the national hemovigilance system in
the UK in 1996–1999 provides data concerning 618 complications associated with the
transfusion of approximately 9 million blood component units (Williamson et al.
2000). Based on this report, over half (54.2%) of the adverse effects were caused by
transfusion of incorrect blood components as a consequence of clerical and identifica-
tion errors. Secondly, transfusion-transmitted infections accounted for 3% of the
complications of transfusion; acute and delayed transfusion reactions for over 25%; and
transfusion-related acute lung injury, post-transfusion purpura, and transfusion-associated
graft-versus-host disease together for 14%.
1.2.1. Immune complications
Hemolytic reactions. The majority of acute hemolytic reactions are due to ABO-
incompatible transfusions, which result from the transfusion of incorrect blood or
blood component as a consequence of clerical or administrative errors. These mistakes
may occur at any stage during the transfusion process; however, the majority of errors
result from misidentification of the patient or the blood component unit before
transfusion (Linden et al. 1992; Williamson et al. 2000; Knowles 2001). Estimates of
the frequency of ABO-incompatible transfusions vary from 1 in 30 000 to 1 in 90 000
(Linden et al. 1992; Williamson et al 2000). According to the UK hemovigilance
system, in 1996 to 1999, four deaths and 29 instances of major morbidity were a result
of 97 ABO-incompatible transfusions (Williamson et al 2000). The results of the
French hemovigilance system are in accordance with these figures (Debeir et al. 1999).
Delayed hemolytic reactions, which are usually due to secondary immune responses
following re-exposure to a given red cell antigen, occur more frequently. However, these
reactions themselves are rarely fatal, although in association with the underlying disease
can lead to mortality (Knowles 2001).
Other immune complications. Of other immune complications listed in Table 2,
transfusion-related acute lung injury (TRALI) occurs most frequently. In the 1996 to
1999 UK hemovigilance report, 39 cases of TRALI were reported, giving an incidence
of approximately 1 in 250 000 transfusions (Williamson et al. 2000). TRALI is charac-
terized by noncardiogeneic pulmonary edema, which, after acute hemolytic reactions,
has been reported to be the second most common cause of fatality or major morbidity
attributed to transfusion (Sazama 1990; Williamson et al. 2000).
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1.2.2. Infectious disease transmission
Viral infections. Five of the main strategies employed to increase the viral safety of the
blood products are: avoidance of unnecessary transfusions, careful selection of blood
donors, screening for viral infections, and virus inactivation and removal procedures
(AuBuchon et al. 1997), and depletion of leukocytes (Bowden et al. 1995). As a result
of improved donor selection and the development of the screening tests, the risk of viral
transmission has decreased markedly (Figure 1).
Figure 1. The risks of transmission of human immunodeficiency virus (HIV), Hepatitis B Virus (HBV)
and Hepatitis C Virus (HCV) in the United States (Goodnough et al. 1999a). Reprinted with
permission.
Donating blood during the period between the actual infection and its possible
detection with the available tests, i.e., the window period, threatens the viral safety of
blood products. The estimated residual risks in unpaid donations in the European
countries are 1 in 2 300 000 for human immunodeficiency virus (HIV), 1 in 600 000
for hepatitis C virus, and 1 in 400 000 for hepatitis B virus (Müller-Breitkreutz 2000).
New screening tests should further reduce the residual risks. In Finland, the nucleic acid
screening for hepatitis C virus has been currently initiated. The residual risks per
donated unit are estimated to be 1 in 1 000 000 for hepatitis B and C viruses, and 1 in
3 500 000 for HIV (Tom Krusius, unpublished data).
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Other infectious agents. Bacterial contamination is most frequent in platelet concentrates, as
the preservation of the viability and function of the platelets requires storage at room
temperature. The rate of contamination of platelet concentrates in Finland has been
reported to be 0.14% in 1997–1998 (Engelfriet et al. 2000).
Although the transmission of variant Creutzfeld-Jakob disease via blood transfusion is
most unlikely (Foster 2000), it has recently raised public concern and, in some European
countries, led to numerous precautions such as donor referral, withdrawals of plasma
and plasma products, and universal leukodepletion.
1.2.3. Transfusion-associated immunomodulation
Allogeneic blood transfusions induce immunomodulatory effects in the recipients
through several mechanisms, possibly related to leukocytes. This immunosuppressive
effect has been found to be beneficial in patients undergoing renal transplantation
(Opelz et al. 1997). However, several observational studies have suggested an association
between allogeneic blood transfusions and both increased rate of postoperative
infections and recurrence of resected malignancies (Blumberg and Heal 1994). Yet,
these findings have not been indisputably confirmed in randomized, controlled studies
(Jensen et al. 1992; Houbiers et al. 1994). Consequently, it is still unsettled whether the
immunosuppressive effect of allogeneic blood transfusions is great enough to be of
clinical significance (Vamvakas and Blajchman 2001).
2. Indications for perioperative blood component transfusion
2.1. Principles of the replacement of acute blood loss
In acute blood loss, resuscitating and maintaining the blood volume is the first priority.
The objectives of transfusion therapy in the acutely bleeding patient are to ensure ad-
equate oxygen delivery to cells and tissues by sufficient hemoglobin concentration, and
to secure hemostasis. This is established by transfusing RBCs, FFP, and platelets according
to individual critical levels (Lundsgaard-Hansen 1980; Murray et al. 1988; Hiippala et
al. 1995).
Acute blood loss up to 20% of the blood volume can be replaced by crystalloid or
colloid solutions (Lundsgaard-Hansen 1980). Because both solutions have their draw-
backs, volume resuscitation is commonly initiated with crystalloids, and colloids are
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combined with crystalloids in the later phase of volume replacement, when the
treatment of colloid osmotic pressure is also needed (Lundsgaard-Hansen 1980). The
use of albumin for primary volume replacement does not yield extra benefit and may
carry additional risk (Cochrane Injuries Group Albumin Reviewers 1998).
As blood loss increases further, the transfusion of RBCs to maintain the oxygen-carrying
capacity of the blood is indicated. There is, however, no universal trigger for RBC
transfusion. When considering the need to increase RBC mass, thought should be given
to the rate and magnitude of blood loss, the patient’s ability to compensate for the
decrease in the oxygen-carrying capacity by increasing cardiac output, and to the factors
affecting oxygen demand (Spahn 2000; American Society of Anesthesiologists 1996).
The concept of the RBC transfusion trigger is discussed in detail on page 19.
When RBCs are used for replacement of massive blood loss instead of whole blood,
dilutional coagulopathy can develop (Murray et al. 1988; Hiippala et al. 1995). The
coagulation factor levels required for adequate hemostasis are 20 to 30% of normal, and
the minimal concentration of fibrinogen between 0.5 and 1.0 g/l (Ciavarella et al.
1987; Murray et al. 1988). Critical fibrinogen levels are reached at a loss and replace-
ment of 1.5 estimated blood volumes, and clotting factor levels at a blood loss of more
than two blood volumes (Hiippala et al. 1995). Although prothorombin time (PT) and
activated partial thromboplastin time (APTT) are already significantly prolonged at a
blood loss of one blood volume (Murray et al. 1988), a clinical bleeding tendency
occurs when APTT and PT exceed 1.5 to 1.8 times control values (Counts et al. 1979;
Ciavarella et al. 1987). In the presence of abnormal bleeding and prolonged clotting
times, correction of the deficiency in fibrinogen and other coagulation factors with FFP
is indicated. To raise coagulation factors over the critical levels, a dose of at least four
units of FFP should be given as a rapid infusion. Additional doses should be given for
each six RBC units transfused (Braunstein and Oberman 1984; American Society of
Anesthesiologists 1996; Hiippala 1998).
The platelet count at which significant bleeding is likely to occur in surgical patients is
unknown,  although a platelet count of 50 x 109/l has often been suggested as a critical
level for adequate hemostasis in these patients (Murray et al. 1988; Leslie et al. 1991).
However, it has also been recommended that, because of the high likelihood of platelet
dysfunction in association with massive transfusion, the platelet concentration in
surgical patients should be maintained at a level greater than 80–100 x 109/l (Spence et
al. 1999). A platelet count of 50 x 109/l is reached after blood loss and replacement of
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over two blood volumes (Hiippala et al. 1995). In the presence of abnormal bleeding
and documented thrombocytopenia, transfusion of 1 unit of platelets per 10 kg of body
weight is indicated (Spence et al. 1999).
Hemostatic abnormalities caused by cardiopulmonary bypass. Bleeding after cardio-
pulmonary bypass (CPB) complicates cardiac surgery: the frequency of severe bleeding
requiring re-exploration of the chest or large transfusion support after CPB approxi-
mates 5% (Cosgrove et al. 1985; Woodman and Harker 1990). Although pre-existing
hemostatic abnormalities and incomplete surgical hemostasis may cause increased
bleeding, exposure of blood to the extracorporeal circuit leads to a multifactorial im-
pairment of the hemostatic system (Woodman and Harker 1990; Kuitunen 1993).
Platelet dysfunction is considered to be the most important contributor to the bleeding
tendency after CPB (Holloway et al. 1988; Despotis and Goodnough 2000). The
decrease in platelet count is of lesser significance. Platelet dysfunction appears to be
dependent on the contact of the platelets with CPB surfaces, resulting in transient
platelet activation. The mechanism of the dysfunction is still unknown, but has been
suggested to involve partial platelet degranulation or defects in platelet surface glyco-
proteins (Harker et al. 1980; Rinder et al. 1991). Excess heparin and hypothermia may
also promote to the platelet dysfunction (Khuri et al. 1992; Khuri et al. 1995). During
CPB, clotting factor levels and the platelet count are usually maintained above critical
thresholds for hemostasis (Harker et al. 1980; Khuri et al. 1992). However, contact
activation may lead to consumption of the coagulation factors and subsequent
fibrinolysis, which further impairs platelet function (Holloway et al. 1988; Chandler et
al. 1995). Finally, residual heparin can inhibit coagulation (Hirsch 1991).
All factors contributing to the hemostatic defect have to be taken into account in the
management of excess bleeding after CPB. After verification of heparin neutralization,
platelet transfusions are generally suggested to be the first priority, followed by
correction of coagulation factor levels with FFP (Gravlee and Hopkins 1988;
Goodnough et al. 1990; Despotis et al. 1994a). Prophylactic transfusions of platelets or
FFP after CPB have been shown to be unwarranted (Simon et al. 1984; Roy et al.
1988). Consequently, if possible, the transfusion of hemostatic components should be
guided by coagulation screening. New on site-coagulation tests may be of value for rapid
analysis of coagulation defects (Despotis et al. 1994a). The recommended thresholds for
platelet and FFP transfusions are platelet count below 100 x 109/l (Goodnough et al.
1990; College of American Pathologists 1994; Despotis et al. 1994a), and APTT and
PT over 1.5 to 1.8 times control values (Counts et al. 1979; Ciavarella et al. 1987).
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Ideally, a test of platelet function should be included. The value of bleeding time as
predictor of surgical bleeding has been criticized (Lind 1991), and methods for better
assessment of platelet function are continuously being sought (Ereth et al. 1998; Shore-
Lesserson et al. 1999). Antifibrinolytic drugs and desmopressin acetate are shown to be
effective in the treatment of bleeding tendency after CPB. The use of hemostatic drugs
is reviewed in section 4.4. on page 36.
2.2. Development of the RBC transfusion trigger
For decades, the “10/30-rule”– hemoglobin concentration 10 g/dl or hematocrit 30% –
has served as a trigger for transfusion of RBCs in the surgical patient. This rule was
based on clinical experience and retrospective studies, in which surgery with lower
hemoglobin levels resulted in poorer outcome (Adams and Lundy 1942; Lunn and
Elwood 1970; Carson et al. 1988). The emerge of HIV infection in the mid-1980’s
forced reconsideration of the transfusion thresholds. Lately, a growing body of evidence
has suggested that lower hemoglobin levels may not lead to increased risk. In healthy
resting humans, isovolemic hemodilution down to a hemoglobin concentration of 50 g/l
did not lead to inadequate oxygen delivery (Weiskopf et al. 1998). Furthermore, in
association with surgery in patients declining blood transfusion, preoperative hemo-
globin levels between 60 to 100 g/l did not increase mortality, provided that blood loss
during surgery was less than 500 ml (Spence et al. 1990). Animal studies have
supported these results (Wilkerson et al. 1988; Levine et al. 1990).
However, the patients with a limited cardiovascular reserve have always been a matter of
concern. In patients with cardiovascular disease, perioperative myocardial ischemic
episodes associated with anemia have been shown to occur frequently (Hogue et al.
1998). The perioperative ischemia often occurs silently without clinical signs (Mangano
et al. 1991). Anemia contributes to adverse surgical outcome in high-risk patients: in a
large retrospective cohort study, patients with ischemic heart disease faced higher risks
of mortality with increasing blood loss and falling hemoglobin levels than did those
without cardiovascular disease (Carson et al. 1996).
In search of an optimal transfusion trigger, the benefits of transfusion have later been
evaluated in observational studies and randomized clinical trials comparing two
transfusion strategies (Table 3). A retrospective study of nearly 9000 elderly hip fracture
patients found no evidence that transfusion would improve survival at hemoglobin
levels greater that 80 g/l (Carson et al. 1998a). However, based on these studies, the
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optimal transfusion strategy in cardiac patients remains a question: there is conflicting
evidence about the safety and benefit of lower hemoglobin or hematocrit (Table 3).
When two hemoglobin-trigger levels were compared in postoperative CABG patients,
no difference was found in morbidity and mortality rates or patients’ self-assessment of
their condition (Bracey et al. 1999). Lower hematocrit values in postoperative cardiac
patients have even been suggested to be beneficial: an observational study categorized
CABG patients in three hematocrit groups on entry to the intensive care unit (ICU)
and found an association between a higher hematocrit and an increased rate of
postoperative myocardial infarction (Spiess et al. 1998). However, in a large study in
ICU patients, a restrictive transfusion protocol was suggested to be superior in younger
and less acutely ill patients, but not in patients with cardiac disease (Hébert et al. 1999).
Table 3. Randomized studies comparing two transfusion strategies.
No. of
  Reference patients Setting Protocol Conclusion
Johnson et al. 1992 39 CABG Achieving Hct 32% vs. No correlation between Hct
transfusions for Hct <25% value and postoperative exercise
capacity
Bush et al. 1997 99 Vascular Maintaining Hb 100 g/l vs. Lower Hb tolerated without
surgery 90 g/l adverse outcome as measured by
mortality, morbidity, and length
of hospital stay
Carson et al. 1998b 84 Hip fracture Postoperative Hb <100g/l ⇒ Fewer units and lower Hb in the
transfusions for symptoms of symptomatic group but higher
anemia or Hb <80 g/l vs. mortality at 60 days
maintaining Hb 100 g/l
Bracey et al. 1999 428 CABG Postoperative transfusion if No difference in outcome as
Hb <80 g/l vs. according to measured by morbidity,
physician’s orders mortality, and patients’ self-
(institutional guideline Hb assessment of their condition
<90 g/l)
Hébert et al. 1999 838 ICU Normovolemic patients with Restrictive strategy as effective as
Hb <90 g/l ⇒ transfusions liberal strategy and possibly
for Hb <70 g/l to maintain superior in ICU patients
Hb 70-90 g/l vs. for (exception: those with acute
Hb 100g/l to maintain cardiac disease)
Hb 100-120 g/l
CABG = coronary artery bypass; Hb = hemoglobin concentration; Hct = hematocrit; ICU = intensive care unit
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Besides hemoglobin and hematocrit values, other triggers for RBC transfusion have also
been proposed. As adequate tissue oxygenation is the main goal of RBC transfusions,
invasive monitoring of oxygenation can be used to define individual transfusion triggers
in specific situations (Casutt et al. 1999). However, routine use of invasive monitoring
is not feasible. Symptoms of anemia have also been studied (Toy et al. 2000), and used
as a trigger, as shown in Table 3 in a study by Carson and colleagues (1998b). Toy and
colleagues (2000) detected, in healthy volunteers with normovolemic anemia, an
increased heart rate and decreased self-scored energy, but no hypotension, at hemo-
globin levels ad 50 g/l. With RBC transfusion, these changes were reversed. Changes in
vital signs as a sole transfusion trigger have also been proposed (American College of
Physicians 1992); however, these changes may be masked by anesthetic agents.
Moreover, as stated previously, silent ischemia can occur in the presence of stable vital
signs (Mangano et al. 1991).
2.3. Transfusion guidelines in association of surgery
2.3.1. RBCs
Appropriate use of RBCs has been addressed in several guidelines (National Institutes of
Health 1988; American College of Physicians 1992; Spence 1995; Irving 1995; American
Society of Anesthesiologists 1996; Simon et al. 1998). In these recommendations, the
use of any uniform transfusion trigger for determining the need for perioperative
transfusion is rejected. Instead, guidelines are presented according to different categories
of hemoglobin concentration or blood loss, and sound clinical judgement as well as
consideration of concomitant diseases is emphasized. The only indication for RBC
transfusions is to augment delivery of oxygen to the tissues.
The two most recent guidelines are summarized as follows: The American Society of
Anesthesiologists (1996) states that, in acute anemia, transfusions are rarely indicated if
the hemoglobin concentration is greater than 100 g/l, but required almost without
exception in patients with a hemoglobin less than 60 g/l. In patients with intermediate
hemoglobin levels, the rate and magnitude of blood loss, patient’s cardiopulmonary
reserve, and factors affecting oxygen consumption should be evaluated. In addition to
similar recommendations according to hemoglobin categories, The College of American
Pathologists (Simon et al. 1998) advise transfusing RBCs in the case of rapid blood loss
of 30% to 40% of the patient’s estimated blood volume, and, in the presence of
intermediate hemoglobin concentrations, to transfuse if tachycardia and hypotension
are not corrected with volume replacement or when tissue oxygenation is compromised
22 REVIEW OF THE LITERATURE
(mixed venous O
2 
partial pressure
 
<25 mmHg, oxygen extraction ratio >50% or oxygen
consumption <50% of baseline).
2.3.2. FFP
According to available clinical guidelines (National Institutes of Health 1985; British
Committee for Standards in Haematology 1992a; College of American Pathologists
1994; American Society of Anesthesiologists 1996), the transfusion of FFP is indicated:
1) in bleeding patients for correction of verified coagulation factor deficiency (PT <0.50
or APTT 1.5 times normal), or when coagulation times cannot be measured in a timely
fashion, in patients transfused with more than one blood volume, 2) for correction of
known coagulation factor deficiencies if the specific concentrate is not available, and 3)
for immediate reversal of warfarin effect. For indications 1 and 2, the dosage should be
10 to 15 ml/kg, and 5 to 8 ml/kg for urgent reversal of warfarin therapy. FFP should
not be used in the management of hypovolemia.
2.3.3. Platelets
As was the case in FFP transfusions, guidelines for platelet transfusion (National
Institutes of Health 1987; British Committee for Standards in Haematology 1992b;
College of American Pathologists 1994; American Society of Anesthesiologists 1996;
Norfolk et al. 1998) are based on observational studies and consensus. The guidelines
are summarized as follows: in the surgical setting, it is difficult to determine one single
laboratory value that by itself would ensure prevention of bleeding. When making
platelet transfusion decisions, the type and extent of surgery, the rate of bleeding, and
the factors that may compromise platelet function should be evaluated. Prophylactic
transfusions before surgery may be indicated in patients with thrombocytopenia due to
decreased platelet production when the platelet count falls below 50 x 109/l, but, if the
surgical procedure is associated with a higher risk for bleeding, a platelet count threshold
between 50 and 100 x 109/l is recommended. In association with bleeding, platelets
should usually be transfused if the platelet count falls below 50 x 109/l. In the presence
of major nonsurgical bleeding after cardiopulmonary bypass as well as in neurosurgical
procedures, higher transfusion thresholds may be applicable. In association with massive
transfusion, repeated platelet counts should be performed to guide the transfusion
therapy. An adequate dosage of platelets is 1 unit per 10 kg of body weight.
23ReReRevie REVIEW OF THE LITERATURE
3. Transfusions in selected common elective surgical procedures
Despite active blood conservation efforts, availability of donor blood still is an important
prerequisite for modern surgery. The fields of surgery using the most blood components
are cardiac surgery and orthopedics (Vamvakas and Taswell 1994; Chiavetta et al. 1996).
3.1. Primary total joint replacements
Total joint replacements are a common treatment of hip and knee arthritis in elderly
patients: approximately 1.5 hip replacements per 1000 inhabitants are performed annually
in industrialized countries (OECD 2000). In Finland, the incidence of total hip
replacements (THR) and total knee replacements (TKR) has grown by 25% during the
five-year period from 1993 to 1998 (Rasilainen and Salmela 1995; Nenonen and Rasi-
lainen 1999), and currently, both procedures are performed at the rate of 0.8 per 1000
inhabitants annually (http://www.stakes.fi/stakestieto/hoitojaksot.htm). As a conse-
quence of demographic changes in the population, the demand for these procedures is
likely to increase (Birrell et al. 1999).
The total blood loss in THR operations averages 1000 to 2000 ml (Flordal and Neander
1991; Sirchia et al. 1994; Schmied et al. 1996). In TKR operations, the use of a
torniquet reduces intraoperative blood loss, and the total blood loss is 500 to 1500 ml
(Mylod et al. 1990; Hiippala et al. 1997). Consequently, in these operations RBCs are
the most common components transfused.
Table 4 shows the allogeneic and autologous red blood transfusion rates in primary
THR and TKR operations from the middle of the 1980s until recent years. If a
declining trend is occurring in allogeneic transfusion rates over the years in both
operations, it is slight, and suggests tightened indications for the use of donor blood.
However, in studies comparing groups of autologous donors with groups of patients not
donating autologous blood, total transfusion rates (allogeneic + autologous) are the
same or even higher in the autologous donor groups (Toy et al. 1992; Biesma et al.
1994; Atlas et al. 1994; Churchill et al. 1994; Billote et al. 2000; Feagan et al. 2001).
Consequently, the availability of predonated autologous blood leads to higher total rates
of transfusion, and lower transfusion thresholds seem to be used in association with
autologous transfusions than with allogeneic blood. This can be seen especially well in a
study reporting a significant decrease in blood loss over the study years from 1977 to
1989, with no effect on the total proportion of patients transfused (Atlas et al. 1994).
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Table 4. Allogeneic and autologous blood use in primary total joint replacements.
Patients transfused, %
Number
Reference Study year of allogeneic total (autologous or
patients blood autologous + allogeneic) PABD
THR
Flordal and Neander 1985 212 74 74 –
1991
Surgenor et al. 1991 1986 2415 68 ND ND
Pinkerton et al. 1992 1987–1988 257 a 75 ND ND
Toy et al. 1992 1987–1989 60 60 60 –
189 15 93 +
Biesma et al. 1994 1986–1991 379 72 72 –
116 18 84 +
Atlas et al. 1994 1977 80 91 91 –
1989 80 16 90 +
Churchill et al. 1994 1988 86 51 51 –
147 14 87 +
Sirchia et al. 1994 1990–1992 1647 57 81 +
Pinkerton 1996 1990–1992 349a 78 ND ND
Chiavetta et al. 1996 1991–1992 2545b ND 52 +
Pinkerton et al. 1998 1990–1991 to
1993–1994 713 55 79 +
1994–1995 to
1996–1997 661 38 66 +
Feagan et al. 2001 1995–1996 850 30 30 –
121 7 79 +
Billote et al. 2000 1998–1999 89 33 33 –
142 15 89 +
TKR
Cushner and Friedman
1991 1986–1988 112 38 38 –
Pinkerton et al. 1992 1987–1988 83 a 39 ND ND
Surgenor et al. 1991 1986 1900 46 ND ND
Churchill et al. 1994 1988 116 28 28 –
112 10 73 +
Hasley et al. 1995 1989 3042 ND 51 ND
Pinkerton et al. 1998 1990–1991 to
1993–1994 243 33 54 +
1994–1995 to
1996–1997 202 17 40 +
Feagan et al. 2001 1995–1996 1005 17 17 –
56 7 66 +
Boralessa et al. 2000 1996–1997 187 64 64 –
ND = no data; PABD = preoperative autologous blood donation; THR = total hip replacement; TKR = total knee
replacement.
a Including an undefined proportion of revision procedures.
b Not defined, whether the operations are primary/revision.
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A large multicenter survey by Sirchia and colleagues best describes the transfusion
practices in total hip replacements in European countries (Sirchia et al. 1994); it reports
the transfusions of 1647 patients undergoing primary THR for arthrosis in 31
university hospitals in 10 countries. The median intraoperative blood loss in these
patients was 600 ml and the postoperative blood loss 470 ml. In 7% of the patients,
perioperative blood loss was over 1500 ml. In all, 80.8% of patients received red unit
transfusions: only allogeneic blood was transfused to 56.8% of all patients, 8.4% of
patients received both allogeneic and autologous blood, and in 15.6% of patients,
transfusion requirements could be met with autologous red units. Plasma units were
transfused to 6% of patients. The use of plasma in these operations was concentrated in
the Mediterranean countries. Albumin and artificial colloids were mainly used as a
colloid replacement therapy in central-northern Europe.
A recent study examined changes during the 1990s in RBC transfusion practices in a
Canadian hospital (Pinkerton et al. 1998). This register-based study shows a constant
trend toward decreasing use of RBC transfusions in total hip and knee replacements.
The proportion of patients transfused with allogeneic RBCs as well as any RBCs
decreased significantly in both operations (Table 4). In THR patients, the mean number
of any RBC units transfused per patient fell from 2.47 units in 1990–1991 to 1.71
units in 1996–1997; and in TKR patients, 1.52 units per patient were transfused in
1991–1992 compared to 0.80 units in 1996–1997. A decrease in the rate of transfusion
of any RBC units in total joint replacements from 85% in 1981–1982 to 65% in
1993–1994 in the Mayo Clinic has also been reported by Warner et al. (1998). In the
most recent study, the overall allogeneic transfusion rate in primary THR was only 22%
(Billote et al. 2000). These changes may reflect an atmosphere of increasing awareness
of the risks of blood transfusion, and raise a question whether this trend will lead in
surgical patients to adverse effects of undertransfusion.
In the studies shown in Table 4, approximately 2 units of allogeneic RBCs were
transfused per THR patient. On the basis of these data, it can be concluded that
primary THR procedures give rise to the transfusion of 2 to 4 allogeneic RBC units/
1000 inhabitants per year in the industrialized countries. Approximately half of this
amount is needed to cover primary TKR operations.
3.1.1. Determinants of blood loss and transfusions in orthopedic operations
Several preoperative predictors of blood loss and allogeneic blood transfusions in orthopedic
patients have been identified. These determinants guide blood ordering, and may
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predict which patients are likely to benefit from autologous blood donation or other
blood conservation methods. The significant indicators for allogeneic RBC transfusion
in total joint arthroplasties include preoperative hemoglobin concentration, patient
weight, age, and aspirin use (An et al. 1991; Nuttall et al. 1996; Larocque et al. 1997).
Female gender per se has been reported to be a predictive factor for blood transfusion in
THR and TKR (Surgenor et al. 1991; Churchill et al. 1994; Sirchia et al. 1994). This
has been attributed to the fact that clinicians use the same hematocrit threshold value for
transfusion for both women and men, without taking into account that women have
lower hematocrit values (Friedman et al. 1980a). Naturally, more blood loss occurs in
bilateral versus unilateral operations, and in revision versus primary surgery (Larocque et
al. 1997). The use of cemented TKR prostheses as well as the anterior approach in THR
have been shown to reduce blood loss (Mylod 1990; Keene and Parker 1993). A point score
system for predicting the likelihood of blood transfusion requirements in orthopedics
using independent determinants (type of arthroplasty, primary versus revision surgery,
preoperative hemoglobin concentration, and patient weight) has been developed by
Larocque et al. (1997).
3.2. Coronary artery bypass operations
In western European countries, approximately 0.6 CABG operations per 1000 inhab-
itants were performed in 1998 (Ghosh and Unger 2000). During the five-year period
from 1993 to 1998, the number of CABG operations performed annually in Finland
has increased by 20% (Rasilainen and Salmela 1995; Nenonen and Rasilainen 1999).
Currently, approximately 0.8 CABG operations per 1000 inhabitants are performed
annually in Finland (http://www.stakes.fi/stakestieto/hoitojaksot.htm). Estimated blood
loss in elective CABG surgery has been reported to be approximately 1000 ml
(Goodnough et al. 1991; Surgenor et al. 1992, Sirchia et al. 1994).
The need for blood transfusions in heart operations has decreased radically in the
decades. The average number of whole blood and RBC units transfused per patient in
open-heart operations decreased from 9.3 units per patient in 1971 to 3.2 units per
patient in 1977, in a study of 1769 patients by Bayer et al. (1980). In 1977, less than
4% of patients needed transfusion of hemostatic blood components, i.e., fresh-frozen
plasma or platelets. This decreasing trend in blood usage was due mainly to nonhemic
priming solutions and the acceptance of normovolemic anemia (Verska et al. 1974). In
Finland, the use of blood components in CABG surgery was more generous: in Finnish
university hospitals from 1987 to 1988, a total of 12.3 units of blood components per
patient were transfused to 685 patients (Ebeling et al. 1991).
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Allogeneic blood component transfusion rates in CABG surgery in the 1980s and in the
1990s are shown in Table 5. An overall declining trend in allogeneic transfusion require-
ments can be detected in these series. Very low transfusion rates, however, have already
been reported in the early years (Cosgrove et al. 1985; Øvrum et al. 1991). These
centers used combined autologous blood conservation methods such as acute
normovolemic hemodilution, intraoperative salvage, and reinfusion of mediastinal
drainage postoperatively. In addition, low thresholds for allogeneic blood transfusions
were applied. The European multicenter SANGUIS study reported transfusion rates in
1166 patients undergoing primary CABG in 21 teaching hospitals in nine countries
from 1990 to 1992. The transfusion rates for RBCs, plasma and platelets were 73%
(37.6% allogeneic and 35.5% allogeneic + autologous), 39%, and 8%, respectively. The
allogeneic RBC use was similar in a study of 3216 patients undergoing CABG in 11 US
hospitals in 1988 (Surgenor et al. 1992). In recent years, approximately half the CABG
patients have received allogeneic RBCs, and transfusion of hemostatic blood
components is quite rarely needed (Pinkerton et al. 1998; Bjessmo and Ivert 2000). The
mean number of RBC units transfused per patient from 1996 to 1997, according to the
Pinkerton group, was 1.27.
In cardiac operations as well as in orthopedics, availability of predonated autologous
blood reduces allogeneic blood transfusions but is associated with an increase in
exposure to any transfusion, allogeneic or autologous (Forgie et al. 1998; Dupuis et al.
1999). In the study by Dupuis and colleagues, total transfusion rates (allogeneic or
autologous blood products) were 73% in patients predepositing autologous blood and
36% in the nonpredepositing patients.
3.2.1. Determinants of blood loss and transfusions in cardiac operations
Preoperatively, determinants of excessive transfusion requirements are useful in
identifying those patients undergoing CABG surgery who might benefit from pre-
operative autologous blood donation or other blood conservation strategies. The factors
associated with reduced preoperative red cell volume, i.e., low preoperative hematocrit,
female gender, older age, and smaller patient size have been shown to lead to an
increased need for blood transfusions in CABG surgery (Cosgrove et al. 1985; Paone et
al. 1994; Magovern et al. 1996; Surgenor et al. 1996; Renton et al. 1997; Shevde et al.
2000). Other patient- or surgery-related factors associated with higher likelihood of
transfusion include prolonged duration of CPB and surgery, combined procedures,
increased number of arterial grafts and total number of grafts, coagulation defects,
tobacco use, insulin-dependent diabetes with renal or circulatory manifestations, low
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Table 5. Allogeneic blood component transfusions in elective CABG surgery.
% of patients receiving allogeneic
blood components
Number of Primary/
 Reference Study years patients redo operations  RBCs FFP  Platelets
Cosgrove et al. 1985 1981 441 Primary 10 ND ND
Goodnough et al. 1991 ND 540 Primary 68 33 22
Tyson et al. 1989 1986–1987 42 Primary 100 81 39
1987–1988 52 Primary 75 16 10
Hasley et al. 1995 1987–1988 6812 ND 81a ND ND
Surgenor et al. 1992 1988 3216 Both 74 ND ND
Øvrum et al. 1991 1989–1990 500 Primary 1 2 0
Bracey et al. 1995 1991 196 Primary 65 16 11
1991 63 Redo 77 31 23
Sirchia et al. 1994 1990–1992 1166 Primary 73 39 b 8 b
Paone et al. 1994 1990–1992 947c Primary 41 24 12
1993 314c Primary 26 13 9
Stover et al. 1998 1991–1993 2417d ND 50 6 9
Magovern et al. 1996 1992–1993 2033c Both (Redo 9%) 61 ND ND
Renton et al. 1997 1993 74 ND 93 7 9
Helm et al. 1998 1994 90 Primary 34 13 10
100 Primary 0 0 0
Pinkerton et al. 1998 1990–1991 361 Primary 43 ND ND
1996–1997 634 Primary 47 ND ND
Bjessmo and Ivert 2000 ND 100e Primary 57 18 4
ND 100 Primary 42 15 3
FFP = fresh-frozen plasma; ND = no data; RBC = red cells.
a including autologous units
b including a small proportion of autologous plasma and platelets
c including emergency/urgent operations
d including combined procedures
e patients with unstable angina, urgent operations
left ventricular ejection fraction, and severe clinical complications (Hardy et al. 1991;
Surgenor et al 1996; Despotis et al. 1996; Magovern et al. 1996; Shevde et al. 2000;
Liu et al. 2000). The influence of preoperative use of heparin and aspirin on blood loss
and transfusion requirements is unclear (Bracey et al. 1995; Despotis et al. 1996).
Patients undergoing urgent, emergency, and redo operations have greater blood loss and
require more transfusions than those undergoing first-time elective operations (Hardy et
al. 1991; Bracey et al. 1995; Surgenor et al. 1996; Magovern et al. 1996; Despotis et al
1996).
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3.3. Transurethral resection of the prostate
Transurethral resection of the prostate (TURP) is a common treatment for urinary
obstruction in prostatic hyperplasia. In Finland, approximately 3000 TURP procedures
are performed annually (http://www.stakes.fi/stakestieto/hoitojaksot.htm). In these
procedures, preoperative ordering of RBCs has been shown to cause the main demand
for transfusion resources. In the SANGUIS study, the overall transfusion rate in TURP
procedures was 16%. However, four times as many patients had preoperative
transfusion requests than were transfused (Sirchia et al. 1994).
3.4. Surgical transfusion practice variation
Several authors have reported substantial variation in transfusion practices among
countries and hospitals with respect to patients undergoing fairly standardized surgical
procedures (Table 6). The SANGUIS study reported differences in surgical transfusion
practices when 43 university hospitals in two large geographical areas, central-northern
Europe and the Mediterranean countries, were compared (Sirchia et al. 1994). The use
of albumin and artificial colloids was more common in the former while autologous
blood was utilized to a greater extent in the latter. Wide differences in transfusion rates
in surgical operations, however, have also been observed between hospitals in the same
country, where one would suppose the organization of health care and availability of
blood products to be homogenous (Stover et al. 1998; Sirchia et al. 1994).
Controlling for patient-related and surgical factors has revealed that variability in
transfusion rates among hospitals is more attributable to differences in local practices
than to the heterogeneity of the patient groups (Goodnough et al. 1991; Surgenor et al.
1992; Sirchia et al. 1994; Hasley et al. 1995; Surgenor et al. 1998). In their 18-institute
study, Goodnough et al. (1991) found wide differences between hospitals in the
proportion of their CABG patients discharged with hematocrits of 33% or higher. The
effect of the specific hospital is well documented in the study by Surgenor et al. (1998),
an effect was revealed by regression analysis and confirmed in a highly stratified subset
of patients. In this group of male patients undergoing similar primary CABG procedures,
donor exposures per 100 surgical patients operated on varied between centers from 303
to 984. Also in the SANGUIS study, major differences in transfusion practices between
hospitals in all procedures except TURP and cholecystectomy were detected even after
adjustment for variables such as age, gender, blood loss, and preoperative hematocrit
value (Sirchia et al. 1994). A study of transfusion practices in hip fracture patients
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Table 6. Studies reporting variation in blood component transfusions in surgical procedures.
Percentage of patients transfused
with
Number Number
  Reference Surgical Study year of of
procedure hospitals patients RBCs   Plasma   Platelets
Surgenor et al. 1991 THR 1986 7 2415 54–87 ND ND
TKR 1986 7 1900 33–78 ND ND
Hasley et al. 1995 CABG 1989 78 6812 51–100 ND ND
TKR 1989 78 3042 9–97 ND ND
THR or
replacement of
the femoral head 1989 78 4131 36–95 ND ND
Goodnough et al.
1991 CABG ND 18 540 17–100 0–97 0–80
Sirchia et al. 1994 CABG 1990–1992 21 1166 17–100 0–100 0–38
THR 1990–1992 31 1647 29–100 0–95 ND
AAA 1990–1992 23 693 64–100 0–100 0–12
COLE 1990–1992 28 995 0–79 0–57 ND
TURP 1990–1992 26 1190 0–46 0–15 ND
CHOLE 1990–1992 28 1504 0–8 0–8 ND
Stover et al. 1998 CABG 1991–1993 24 2417 27–92 0–36 0–36
Surgenor et al. 1998 CABG 1992–1993 5 773 9–29 ND 15–55
Audet et al. 1998 Operative repair
of hip fracture or
THR or TKR 1992–1993 5 384 21–54 ND ND
Poses et al. 1998 Operative repair
of hip fracture 1982–1993 20 8776 31–54a ND ND
AAA = abdominal aorta aneurysmectomy; CABG = coronary artery bypass; CHOLE = laparotomic
cholecystectomy; COLE = hemicolectomy; ND = no data; RBC = red cell; THR = total hip replacement; TKR =
total knee replacement; TURP = transurethral resection of the prostate
a Postoperative transfusions
found considerable variation between hospitals in RBC transfusion rates and transfusion
trigger hemoglobin levels (Poses et al. 1998).
The influence of individual surgeons on transfusion practices has not been extensively
studied. Hardy et al. (1991) found very small differences in blood loss and the use of
blood products in cardiac surgery among seven anesthesiologists and nine surgeons.
Dupuis et al. (1999) showed that, in cardiac surgery, having a surgeon who was one of
the five with the significantly highest transfusion rate was among the independent
determinants for exposure to allogeneic blood. In a study by Surgenor et al. (1998),
transfusion practices were found to be variable between hospitals (Table 6), but uniform
among individual surgeons within hospitals. The effect of the specific hospital seems to
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be the result of institutional differences in transfusion policies and in physician training.
In the USA, national guidelines for blood transfusions in cardiac procedures have
existed since the 1980s (National Institutes of Health Consensus Conference 1985,
1987, & 1988). In 1991, considerable heterogeneity in transfusion practices in CABG
between hospitals was detected, and the appropriateness of transfusion practices was
questioned (Goodnough et al. 1991). The effect of these recommendations on transfusion
practices in CABG surgery was evaluated in a recent 24-institute US study (Stover et al.
1998). Significant variation in the transfusion rates between institutions persisted
despite the national recommendations. The hospital was still revealed to be a major
significant independent determinant of blood transfusion practices.
This variation in transfusion practices may place patients at risk for unnecessary blood
transfusions and may lead to substantial differences in blood product costs between
hospitals. In the SANGUIS study, the mean blood product cost per CABG patient
varied over six-fold between hospitals (Sirchia et al. 1994). However, as there are few
studies on the risks versus benefits of blood transfusion, the optimal transfusion
practices are difficult to define (Carson et al. 1998 a and b). Consequently, although
the hospitals with high transfusion rates may have incurred more costs and adverse
effects, it is possible that their patients may have benefited more.
4. Blood conservation in surgery
4.1. Surgical and anesthesiological considerations
For effective blood conservation, the contribution of the whole surgical team is
necessary. Careful surgical hemostasis and atraumatic technique lessen intraoperative
blood loss. The choice of anesthesia method may promote blood conservation: in THR
operations, less blood loss has been shown to occur in THR operations performed under
regional anesthesia than under general anesthesia (Modig 1988). Moreover, in THR,
hypotensive epidural anesthesia reduces perioperative blood loss and transfusion
requirements (Sharrock and Salvati 1996). Prevention of perioperative hypothermia is
also of importance: hypothermia has been shown to increase blood loss and transfusions
in THR operations, and active warming may reduce blood loss (Schmied et al. 1996,
Winkler et al. 2000). Finally, in order to optimize the use of blood products, careful
case-by-case consideration is needed of the patient’s individual RBC transfusion
threshold (American Society of Anesthesiologists 1996).
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4.2. Autologous blood
Since the recognition of HIV-infection, use of autologous blood to decrease risk for
transfusion-transmitted infections has gained support in many countries, especially in
the USA. After the initial enthusiasm in the 1980’s (Surgenor et al. 1990; Wallace et al.
1995), however, the usage of autologous blood has decreased. The improved safety of
allogeneic blood and the current pressure on cost containment have contributed to this
tendency. Recently, approximately 4% of all transfusions in the USA have been reported
to be autologous (Wallace et al. 1998). Autologous blood can be collected in various ways:
by donation of blood before elective operation, by collection of 1 to 2 units of blood
prior to, or concomitant with, the induction of anesthesia with simultaneous volume
replacement, or by the salvage of blood lost during or after surgery. Combinations of
these methods are also being used, especially in cardiac surgery (Øvrum et al. 1991).
4.2.1. Preoperative autologous blood donation
Preoperative autologous blood donation is recommended in patients undergoing elective
surgery if there exists a reasonable chance (at least a 50% likelihood) of transfusion in
connection with the procedure. Blood units are usually donated at weekly intervals, and
oral iron supplementation is continued until surgery. As a minimum, viral screening
should be performed at the first and last donation (British Committee for Standards in
Haematology Blood Transfusion Task Force 1993; Thomas et al. 1996). The use of re-
combinant human erythropoietin therapy has been suggested as an adjunct to preopera-
tive autologous blood donation to allow a greater number of units to be collected
(Mercuriali et al. 1993). Later, the use of recombinant human erythropoietin in associa-
tion with preoperative autologous blood donation has been questioned (de Pree et al. 1997).
The efficacy of preoperative autologous blood donation in reducing allogeneic blood
exposure has been shown in both cardiac and orthopedic surgery as well as in major
urological operations (Pinkerton and Klotz 1995; Sandrelli et al. 1995; Hatzidakis et al.
2000).
Risks associated with blood donation have been shown to be greater in autologous
donors than in the healthy, selected voluntary donor population. Very severe outcomes,
defined as events requiring hospitalization, have been shown to occur in autologous
donations at a rate of 1 in 16 783. This risk, however, was 12 times as high as the risk
associated with voluntary donations by healthy individuals. Elderly and first-time
donors were more prone to complications (Popovsky et al. 1995).
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Based on known risks of allogeneic blood transfusion, the cost-effectiveness of
autologous blood donations is low. The additional costs compared to those of allogeneic
blood are mainly related to a high wastage rate of autologous units (Birkmeyer et al.
1993; Etchason et al. 1995).
Given the greater safety of autologous blood, it has been suggested that the hemoglobin
threshold for autologous transfusion should be higher than that for allogeneic blood
(Miller and von Ehrenburg 1995, American Society of Anesthesiologists 1996). On the
other hand, as all transfusions incur risks, identical thresholds have also been
recommended (Gould and Forbes 1995). In clinical practice, higher transfusion
thresholds for autologous blood seem to be applied; the availability of autologous blood
has been shown to decrease allogeneic transfusions but increase exposures to any
transfusion, allogeneic or autologous (Forgie et al. 1998).
4.2.2. Acute normovolemic hemodilution
Acute normovolemic hemodilution (ANH) is defined as the removal of whole blood
immediately before or shortly after induction of anesthesia, with simultaneous replace-
ment with crystalloids or colloids to maintain intravascular volume. During surgery,
after major blood loss has ceased, these blood units are returned to the patient. The
rationale of ANH comes from the fact that after hemodilution, perioperative red blood
cell loss is lower than it would be with a higher hematocrit value. In addition, as a result
of decreased blood viscosity, ANH may enhance tissue perfusion (Messmer 1975). ANH
has been recommended for a patient with a preoperative hemoglobin concentration over
110 g/l and a potential blood loss over 20% of blood volume (British Committee for
Standards in Haematology Blood Transfusion Task Force 1997).
As a collection method for autologous blood, ANH offers several advantages over pre-
operative autologous blood donation. The costs of ANH are lower, because the units
collected need not be screened for viral markers, and, since all units are returned to the
patient, the wastage of autologous units is eliminated (Monk et al. 1995; Goodnough et
al. 1998).
The efficacy of limited hemodilution has been questioned by use of mathematical
modeling. According to Brecher and Rosenfeld (1994), extreme hemodilution with a
target hematocrit of 20% should be used to achieve savings of less than one unit of
RBCs. However, in three current prospective randomized trials, the effectiveness of
acute normovolemic hemodilution in reducing allogeneic blood exposure in orthopedic
34 REVIEW OF THE LITERATURE
and urological surgery has been shown to be equal to preoperative autologous blood
donation (Table 7). These studies used limited hemodilution with a target hematocrit of
28%. On the other hand, the value of ANH has also been questioned in a recent meta-
analysis: In trials using a transfusion protocol for perioperative blood replacement,
ANH failed to reduce transfusion requirements (Bryson et al. 1998).
Table 7. Three current prospective randomized trials comparing the efficacy of acute normovolemic
hemodilution  and preoperative autologous blood donation.
Allogeneic blood
Sample size exposure, %
Author Surgery ANH PABD ANH PABD P
Monk et al. 1999 Radical prostatectomy 26 26 19 15 NS
Goodnough et al. 1999b Total knee arthroplasty 15 17 47 25 NS
Goodnough et al. 2000 Total hip arthroplasty 23 25 17 0 NS
ANH = acute normovolemic hemodilution; PABD = preoperative autologous blood donation; NS = not significant.
4.2.3. Blood salvage
Intraoperative blood salvage involves salvaging of blood lost during surgery and
reinfusing red cells processed with a cell-washing device. The oxygen transport properties
and survival of recovered RBCs has been shown to be comparable to those of allogeneic
RBCs (McShane et al. 1987; Umlas et al. 1993). The contraindications of intraopera-
tive salvage include bacterial contamination in the operative field and the presence of
malignant cells or other contaminants (British Committee for Standards in Haematol-
ogy Blood Transfusion Task Force 1997). The use of intraoperative blood salvage may
impair hemostasis (Horst et al. 1992).
Intraoperative salvage may be beneficial in surgical procedures with acute blood loss of
more than 1000 ml (Stehling et al. 1996; Goodnough et al. 1996). Although some
studies report a reduction of 1 to 2 units in allogeneic transfusion requirements with
intraoperative salvage compared to that of the control group (Elawad and Fredin 1992;
Patra et al. 2000), the efficacy and cost-effectiveness of intraoperative salvage has
recently been repeatedly questioned (Clagett et al. 1999; Goodnough et al. 1996).
Postoperative blood salvage is a technique involving collecting and reinfusing blood shed
from mediastinal, chest and joint drains, generally without washing (Stehling et al.
1996). Shed mediastinal blood has undergone fibrinolysis, so no anticoagulation is
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needed before transfusion (Eng et al. 1990). Due to the collection method, the un-
washed salvaged blood may include various contaminants. The coagulation and
fibrinolysis systems are also activated (Robbins et al. 1992; Kristiansson et al. 1995).
As is the case in intraoperative salvage, the efficacy of postoperative blood salvage in
both orthopedic and cardiac surgery is uncertain. There are studies reporting a decrease
in allogeneic blood requirements by using postoperative salvage (Gannon et al. 1991;
Martin et al. 2000), as well as studies showing lack of efficacy (Ward et al. 1993; Umlas
et al. 1994). According to a recent meta-analysis, postoperative salvage and reinfusion
seems to reduce allogeneic exposures in orthopedic surgery. In cardiac patients, the
efficacy of postoperative transfusion of unwashed salvaged blood is negligible (Huët et
al. 1999).
4.3. Artificial oxygen carriers
Two types of artificial oxygen carriers, hemoglobin-based solutions and perfluorocarbon
products, have long been under development (reviewed by Prowse 1999). Because of
their short half-life, these products are useful only in acute situations. However, they
may have the potential properties of an ideal solution in such settings: oxygen carrier,
volume expander, no viral risks, no blood group properties, and storage at room
temperature.
Yet, in practice, the development of hemoglobin solutions has encountered numerous
drawbacks related, in addition to short intravascular persistence, also to renal toxicity
and vasoactive effect. Some of these problems have been solved, and at present, half a
dozen hemoglobin solutions are undergoing clinical trials to assess their ability to reduce
RBC transfusions in trauma or in the perioperative setting. It is of note that one of the
trials was recently interrupted due to an excess of deaths in the test group.
In human and canine models of acute anemia, the transfusion-sparing potential of
perfluorocarbon solutions has been suggested. However, this effect was shown only
under very standardized conditions, which are unlikely to occur in clinical practice.
Currently, one perfluorocarbon product is in a phase III clinical trial for its potential to
reduce perioperative transfusion requirements. Future applicability of perfluorocarbon
solutions in combination with ANH has also been suggested (Spahn 1999).
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4.4. Hemostatic agents
4.4.1. Tranexamic acid
Tranexamic acid is a synthetic antifibrinolytic amino acid which inhibits binding of
plasminogen to fibrin and therefore its activation to plasmin. Consequently, the
degradation of fibrin is precluded. Traditionally, tranexamic acid has been used in urologic
surgery (Miller et al. 1980). In orthopedics, tranexamic acid has proven especially
effective in reducing both blood loss and transfusion requirements in TKR operations in
which the use of a pneumatic torniquet enhances local fibrinolytic activity in the limb
(Hiippala et al. 1997; Petäjä et al. 1987). The allogeneic blood-sparing effect of prophy-
lactic tranexamic acid has also been shown in cardiac surgery in which fibrinolysis is in-
creased as a result of CPB (Katsaros et al. 1996; Brown et al. 1997). Tranexamic acid
may increase risk for thrombosis (Mannucci 1998), although no such association has been
detected in recent studies (Katsaros et al. 1996; Brown et al. 1997; Hiippala et al. 1997).
4.4.2. Aprotinin
Aprotinin is a serine protease inhibitor which blocks the action of enzymes such as
trypsin, plasmin, and kallikrein (Fritz and Wunderer 1983). In cardiac surgery, aprotinin has
been suggested to inhibit contact activation and to preserve platelet glycoprotein
receptors (van Oeveren et al. 1987 & 1990). The effect of prophylactic aprotinin in
reducing bleeding and transfusion requirements in all types of cardiac surgical patients
has been shown in several randomized, double-blind studies (Bidstrup et al. 1989 and
2000; Levy et al. 1995). However, a similar blood conservation effect at significantly
lower cost was achieved with tranexamic acid (Casati et al. 2000). Currently, optimal
dose regimens are being sought to increase the cost-effectiveness of aprotinin therapy
(Beath et al. 2000). Other clinical applications of aprotinin include revision and
bilateral total hip replacement and orthotopic liver transplantation (Capdevila et al.
1998; Porte et al. 2000)
4.4.3. Desmopressin acetate
Desmopressin acetate (1-deamino-8-d-arginine vasopressin, DDAVP) transiently increases
the plasma concentrations of factor VIII and von Willebrand factor by stimulating
endogenous production. DDAVP can be used to treat mild bleeding episodes in patients
with hemophilia A and most types of von Willebrand’s disease (Mannucci et al. 1981).
After routine primary CABG, most randomized studies show no effect of DDAVP on
transfusion requirements. On the other hand, DDAVP has been proven effective in
cardiac surgical patients with excessive perioperative bleeding and drug-induced platelet
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dysfunction (Mongan et al. 1992; Cattaneo et al. 1995). A recent meta-analysis
suggested that use of DDAVP is associated with an increased risk for perioperative
myocardial infarction (Levi et al. 1999).
4.4.4. Fibrin sealant
Fibrinogen and thrombin are the two main components of fibrin sealant. In addition,
fibrin sealant may include inhibitors of fibrinolysis such as aprotinin or tranexamic acid.
When mixed together, thrombin reacts with fibrinogen to form a fibrin clot (Martino-
witz and Spotnitz 1997). Fibrin sealant is used for control of oozing in all fields of
surgery (Spotnitz et al. 1989; Levy et al. 1999).
5. Education and audit in transfusion medicine
In numerous consensus conferences in different countries, expert opinions on transfusion
indications have been formulated into authoritative guidelines for blood component
transfusion (Irving 1995; American Society of Anesthesiologists 1996; Simon et al.
1998). However, as in other fields of medicine (Lomas et al. 1989; Grimshaw and
Russell 1993), guidelines have often failed to alter clinical practice. Wide variation in
transfusion practices has been shown to persist despite national consensus guidelines
(Stover et al. 1998). This can be attributed to the fact that due to the lack of precise
evidence-based data, guidelines give rather general recommendations as to the indications
for blood component usage. In addition, as transfusion practices are thought to be
largely affected by local opinion, local input is needed to implement the guidelines
(Grimshaw and Russell 1993; Gundersen 2000).
Medical practice audits and education can serve as powerful tools to increase the
appropriateness of transfusion policies. The goals of transfusion practice audits are
presented in Table 8.
Table 8. Objectives of transfusion practice audits.
1. Modification of physician behavior in the area of transfusion therapy
2. Improvement of the standards of transfusion practice in the hospital
3. Identification and implementation of more cost-effective procedures
4. Compliance with regulatory agencies, which require audits and quality assurance activities
5. Establishment and enforcement of uniform transfusion practices throughout the hospital
6. Provision of data on transfusion practice
7. Monitoring therapeutic and adverse effects of transfusion
Modified from Petz and Swisher 1996.
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5.1. Administrative issues
5.1.1. Hemovigilance
Hemovigilance is a national surveillance and monitoring system based on continuous
collection and analysis which aims at: 1) monitoring all adverse effects associated with
the blood chain from collection to transfusion, including transfusion errors, and 2)
incorporating information on the prevalence and incidence of infectious markers in
blood donors, and on the total number of patients and of blood components that have
been transfused. The goals are to improve the safety of blood transfusions, and to
optimize the indications for blood transfusion (Debeir et al. 1999; McClelland 1998).
Hemovigilance organizations have been established in several European countries, either
based on legal obligation, as in the French system, or on the voluntary reporting used in
the UK program (Debeir et al. 1999; Williamson et al. 2000). In Finland, no official
hemovigilance organization has yet been established, but adverse effects of blood
transfusion are reported to the Finnish Red Cross Blood Transfusion Service by the
clinicians on a voluntary basis.
Although the hemovigilance concept as such is not used in the USA, continuous blood
usage review, and monitoring and reporting of blood components effects has been part
of the practice for a long time, and is required by several state and national authorities
(Menitove 1998; American Association of Blood Banks 1999).
5.1.2. Hospital transfusion committees
The formation of special hospital transfusion committees has been recommended
(American Association of Blood Banks 1994; Council of Europe 2001). A hospital
transfusion committee is responsible for developing transfusion practice guidelines
adapted to local clinical activities and conducting a blood utilization review to monitor
the safe and effective use of blood products. The committee also should play a central
role in the education of clinical staff. The members of the committee ideally represent
all major specialties undertaking significant transfusion activity: surgery, obstetrics,
anesthesiology, internal medicine and pediatrics. Subspecialties such as cardiovascular
surgery, intensive care, hematology, and oncology can also be included. Representatives
of the hospital blood bank and the blood transfusion service should also serve on the
committee (Grindon et al. 1985; Silberstein et al. 1989; American Association of Blood
Banks 1994; Petz and Swisher 1996; Council of Europe 2001).
39ReReRevie REVIEW OF THE LITERATURE
5.2. Audit and educational methods
5.2.1. Targeting education
In a face-to-face survey of surgeons and anesthesiologists, lower knowledge scores in
transfusion medicine were found among the group of attending physicians than among
residents (Salem-Schatz et al. 1990). However, residents’ transfusion decisions were
strongly influenced by the attending physicians’ opinions, and 61% of the residents
surveyed admitted that, at the attending physician’s suggestion, they frequently ordered
transfusions that they personally judged unnecessary.
5.2.2. Transfusion practice reviews
Retrospective review. Retrospective audits are conducted several weeks or months after
the transfusion episode. This type of audit is useful in assessing large-scale trends and
reviewing overall hospital transfusion practices. The results of these audits are of value
in identifying areas of practice that could be improved by education (American Associa-
tion of Blood Banks 1994; Mintz 1995). Availability of data in the patient charts places
restrictions on retrospective data collection (Sirchia et al. 1994; Audet et al. 1996).
Several chart-review studies report appropriateness rates of transfusions varying from
45% to 65% based on preset criteria (Ghali et al. 1994; Saxena et al. 1993; Sudhindran
1997). However, because information in the charts on indications for transfusion is
often lacking, determination of the appropriateness of blood transfusions on the basis of
retrospective chart review is difficult. Therefore, the value of these studies is question-
able; they mainly serve as a basis for future audits and education (Audet et al. 1996).
Although the retrospective peer review system per se is not effective in decreasing
inappropriate practices (Lam et al. 1996), retrospective review with effective feedback
after auditing and introduction of institutional transfusion policies has been shown to
reduce unnecessary blood transfusions (Brandis et al. 1994). By using hospital registers,
retrospective audits can be performed without time-consuming chart review (Hasley et
al. 1995; Zimmermann et al. 1997; Pinkerton et al. 1998).
Prospective and concurrent reviews. Improvements in transfusion practices have been
achieved by use of prospective and concurrent (12–24 hours after transfusion) reviews.
Rehm et al. (1998) reported a 26% decrease in the number of RBC units transfused at a
teaching hospital because of a mandatory blood ordering form based on National
Institutes of Health consensus guidelines. Previously, voluntary use of blood ordering
forms resulted in no changes. The uselessness of prospective study as short as three
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months which utilized a physician self-audit blood component request form was
demonstrated (Lam et al. 1997); blood component use reduced during the three-month
intervention, yet, even one month afterwards, the effect had disappeared. There is,
however, some evidence that a continuous review process can achieve sustained
improvement in transfusion practices (Silver et al. 1992).
Prospective reviews may be performed most elegantly in a computerized manner. A
decrease in inappropriate plasma requests from 39% to 14% was achieved in a study
using a computerized prospective audit, in which the computerized blood request
program was linked with a patient’s clinical and laboratory data (Marconi et al. 1996).
Furthermore, combining computerized ordering with written transfusion guidelines
communicated to the medical staff by a letter, and regular monthly transfusion
medicine specialist consultations has resulted in marked reduction of allogeneic blood
exposure and in cost savings (Rosen et al. 1993).
5.2.3. Face-to-face visits, lectures and rounds
Face-to-face visits are an effective but time-consuming audit method widely used by
pharmacological companies. In their controlled, randomized study, Soumerai et al.
(1993) reported a decrease during a six-month follow-up in the mean hematocrit
threshold as well as in inappropriate RBC transfusions after an educational program.
The educational intervention consisted of printed guidelines, a lecture emphasizing
prudent indications for blood transfusions, face-to-face educational visits, and rounds.
Shanberge (1987) conducted plasma rounds on patients transfused with FFP and
discussed inappropriate transfusions individually with the physician involved. Individual
education was supported with seminars. The educational program resulted in a 77%
decrease in the number of plasma units transfused during two years.
Traditional lectures have also been shown effective in decreasing inappropriate blood
use, especially when combined with other methods such as initial retrospective
utilization review, a blood component order form, implementing of transfusion guidelines
or discussion of transfusion decisions at grand rounds and weekly conferences (Barnette
et al. 1990; Morrison et al. 1993).
5.2.4. Questionnaire studies
Three studies have used questionnaires to investigate transfusion decision-making. The
transfusion indications used by anesthesiologists varied significantly in a study by
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Stehling et al. (1987). At that time, over 40% of the anesthesiologists responded that
they would transfuse prior to loss of 20% of estimated blood volume. Another study
used hypothetical clinical cases to explore the differences between two hospitals in
transfusion decisions. At a hemoglobin concentration of 99 g/l, surgeons were four
times as likely to transfuse RBCs as were physicians or anesthetists (Nicholls and Whyte
1993). A recent questionnaire study showed that low hemoglobin was the prevailing
trigger for RBC transfusion in Scotland (Garrioch et al. 2000). With blood transfusion,
the clinicians still most commonly aimed at a target hemoglobin of 100 g/l.
5.2.5. Transfusion algorithms
Inappropriate transfusion practices may in part be due to the lack of laboratory data at
the time of the decision-making. Consequently, transfusions are given on an empirical
basis. Intraoperative treatment algorithms based on rapid on-line coagulation measure-
ments have been suggested to serve as effective tools to guide transfusion decisions
(Despotis et al. 1994b; Shore-Lesserson et al. 1999). In these two randomized clinical
trials in bleeding cardiac surgical patients, fewer transfusions were given to the patients
in the algorithm group than in the case of standard replacement therapy guided by the
laboratory measurements that appeared necessary to the clinician.
5.2.6. Blood ordering practices
The maximum surgical blood-ordering schedule is a list of number of blood component
units that should ordinarily be crossmatched before most common elective surgical
procedures. This schedule should be based on each hospitals’ local transfusion practice
and be prepared in cooperation with the surgical staff. It must be updated regularly to
reflect the changes in institutional blood transfusion practices. As a guideline, the
number of blood units crossmatched before the operation should meet the intraopera-
tive transfusion requirements in ≥90% of the patients (Stehling 1982; American
Association of Blood Banks 1994; Shulman et al. 1996). A crossmatch-to-transfusion
ratio can measure the appropriateness of the schedule. A crossmatch-to-transfusion ratio
of  ≤2 is usually considered as appropriate (American Association of Blood Banks 1994).
Auditing and reorganization of blood ordering practices has been effective in decreasing
the initially high crossmatch-to-transfusion ratio (Rouault and Gruenhagen 1978).
42 AIMS OF THE STUDY
AIMS OF THE STUDY
The general purpose of the present study was to examine the transfusion practices in
elective surgical procedures in Finnish hospitals, to identify areas of practice that may
need improvement, and to seek methods to guide the transfusion practices.
The following issues were of particular interest:
1. To determine the rates of transfusion and the transfusion thresholds applied to the
administration of blood components in common elective surgical procedures in
Finnish hospitals.
2. To evaluate the rate of and the reasons for variation in the surgical transfusion
practices between hospitals.
3. To describe the use of blood conservation methods in Finnish hospitals.
4. To study the effect of a treatment algorithm with timely laboratory monitoring on
transfusion practices in cardiac surgical patients.
5. To evaluate the blood transfusion trends in CABG operations in a university
hospital by use of transfusion data automatically stored in hospital registers.
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MATERIALS AND METHODS
Patients and study designs
Ethical considerations
Permission to conduct Studies I to III was given by the Ministry of Social Affairs and
Health in Finland. The ethics committee of the Finnish Red Cross Blood Transfusion
Service also accepted the plan for Studies I to III. The research protocol of Study IV was
approved by the Helsinki University Central Hospital’s Ethics Committee. In addition,
written informed consent for participation in Study IV if excessive bleeding occurred
after CPB was obtained from 1412 adult patients scheduled to undergo elective cardiac
surgery.
Studies I to III
Studies I to III were undertaken to determine the transfusion practices in common
elective surgical procedures in Finland. In these studies, patient records of a total of
2308 patients admitted for elective surgical procedures in 16 Finnish hospitals from
1993 to 1994 were reviewed by five anesthesiologists. The surgical procedures included:
first-time elective non-combined CABG (n=804; III), primary unilateral THR (n=764;
I, II) and TKR (n=397; I, II) for primary arthritis, and TURP (n=343; II) for prostate
adenoma. The first three procedures were selected because they are frequently
performed and often involve blood transfusion. TURP was studied as representing a
surgical procedure for which blood is often ordered but rather rarely transfused. The
hospitals and the distribution of the surgical procedures are shown in Table 9. The THR
and TKR patients were the same in Studies I and II. The study hospitals included all
five Finnish university hospitals, and seven non-teaching hospitals representing different
regions. All hospitals performing CABG surgery were audited, and in addition, a large
private orthopedic clinic was included. Based on a preliminary survey of blood use and
rates of surgery in Finnish hospitals, these hospitals were assumed to represent different
surgical transfusion practices.
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Table 9. Participating hospitals in Studies I to III.
Hospital Surgical procedures Study  number
type studied
Central Finland Central Hospital, Jyväskylä N-T THR, TURP I, II
Cordia Hospital, Kuopio P CABG III
The Deaconess Institute Hospital, Helsinki P CABG III
Helsinki City Hospital, Helsinki N-T THR I, II
Helsinki University Central Hospital, Helsinki U CABG, THR I–III
Kuopio University Hospital, Kuopio U CABG, THR I–III
Lahti District Hospital, Lahti N-T THR, TURP I, II
Mehiläinen Hospital, Helsinki P CABG III
Orton Hospital, Helsinki P THR, TKR I, II
Oulu University Central Hospital, Oulu U CABG, TURP II, III
Salo District Hospital, Salo N-T TKR I, II
South Bothnian Central Hospital, Seinäjoki N-T THR, TKR I, II
South Carelian Central Hospital, Lappeenranta N-T TKR I, II
Tampere University Hospital U CABG, TKR I–III
Turku University Hospital, Turku U CABG III
Vaasa Central Hospital, Vaasa N-T CABG, THR, TURP I–III
CABG = coronary artery bypass; N-T = non-teaching hospital; P = private hospital; THR = total hip replacement;
TKR = total knee replacement; TURP = transurethral resection of the prostate; U = university hospital.
All patients who had undergone these elective surgical procedures were included in the
study. However, if the number of operations performed over the 24-month period
exceeded 80 in a particular hospital, only the first four or five eligible patients operated
on in each month were reviewed to form groups of a minimum of 80 patients. The
exclusion criteria were: pre-existing coagulation disorders, preoperative heparin infusion
or fibrinolytic therapy and admission for more than one elective surgical procedure
during the episode of care. In all, 52 out of 2360 patients (2.2%) were excluded from
the study because their charts were unavailable for review at the time of the study.
Demographic data compiled included patients’ age, gender, and body weight and
height. Total blood volume was calculated by a weight-based approximation (I, II). In
Study III, red cell volume (calculated blood volume multiplied by preoperative
hematocrit) was recorded. Preoperative aspirin exposure and data on the administration
of hemostatic drugs during and after the operation were recorded in Study III.
Operative data compiled in Study III included CPB time, number of grafts and chest
tube drainage 16 h postoperatively. In Studies I and II, operative data was recorded as
follows: method of anesthesia (I), duration of the operation (I), blood loss during
operation (I, II) and total blood loss (I, II). In all three studies, the data concerning
allogeneic and autologous blood transfusions was identified from the patient records.
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Fluid therapy was also registered. Hemoglobin and hematocrit values were recorded as
follows: 1) preoperative value (I–III), 2) lowest value during CPB (III), 3) lowest value
after surgery during the day of operation (III), 4) value on the first postoperative morning
(III), 5) lowest value during the postoperative stay (II, III), and 6) last recorded value before
discharge from the hospital after all transfusions had been given (I–III). Data concerning
patient outcome was registered in all three studies. In the results, the hospitals are
numbered according to the ascending number of allogeneic RBC units transfused per
patient.
Study IV
Study IV was designed to evaluate the effect of treatment, based on an algorithm with
rapid on-line coagulation monitoring versus the standard therapy, on blood loss and
transfusions in bleeding patients after cardiac surgery. The study was carried out in
Helsinki University Central Hospital during a 15-month period from 1996 to 1998. All
the patients undergoing cardiac surgery were considered eligible for the study, irrespective of
type of surgery or preoperative bleeding history. Patients were excluded only if no
personnel were available to perform on-site coagulation monitoring.
Standard anesthesia and tepid hypothermic (32-34°C) CPB were employed. During
bypass, activated clotting time (ACT) was maintained over 400 seconds. After the termina-
tion of CPB, heparin was neutralized with 1 mg of protamine per 100 IU of heparin.
After heparin neutralization, any bleeding tendency was evaluated as follows: if the
patient bled more than 1.5 ml/kg/15 min after the mediastinal drains were emptied for
the first time, bleeding was considered abnormal. Patients who met this criterion were
then randomized into two groups. The algorithm group (n=29) was treated according
to an algorithm based on on-site coagulation monitoring (Figure 2). The algorithm was
followed during the immediate recovery period (one hour after surgery). Whole blood
APTT and PT were measured with a portable Thrombolytic Assessment System (TAS,
Cardiovascular Diagnostics Inc., Raleigh, NC, USA) as described in detail in Study IV.
The transfusion thresholds for RBC, platelets, and FFP used in the algorithm were
based on recent recommendations (American Society of Anesthesiologists 1996;
Robertie and Gravlee 1990), and also followed the hospital’s standard practice. One
patient with massive intra-and postoperative bleeding was excluded from the algorithm
group, because he could not be treated according to the protocol. The control group
(n=30) received the treatment routinely given to a bleeding post-CPB patient in this
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hospital. The use of coagulation tests was prohibited; only the routine ACT measure-
ment after heparin neutralization was allowed.
In the ICU, the patients of both groups were treated and laboratory tests made
according to the clinician’s discretion. But in the ICU and on the surgical ward, the
hemoglobin concentration was measured before each RBC unit transfused, and the
transfusion threshold was kept at 90 g/l.
Hemoglobin
<90 g/l
Platelets
<100 x 109/l
Whole blood
APTT or PT 1.5 x
normal value
ACT over 10 s
longer than
preoperative ACT
Bleeding time
>12 min.
Normal values in
all previous tests
1 unit of RBCs
New hemoglobin measurement
before each RBC unit
1 unit of platelets / 10 kg, round
up to the nearest full 4 units
FFP 10 ml/kg
(whole units)
Protamine 0.5 mg/kg
DDAVP 0.3 µg/kg
Tranexamic acid 10 mg/kg
Yes
Yes
Yes
Yes
Yes
Yes
No
Figure 2. Treatment algorithm (algorithm group). The triggers for FFP transfusion were whole blood
APTT ≥53 s or PT≥ 20s. ACT = activated clotting time; APTT = whole blood activated partial
thromboplastin time; DDAVP = desmopressin acetate; FFP = fresh-frozen plasma; PT = whole blood
prothrombin time; RBC = red cell.
All 1412 elective cardiac surgical patients were advised to discontinue the use of
platelet-inhibiting drugs one week before surgery. Nevertheless, one patient in the
algorithm group and three patients in the control group had taken aspirin within one
week before the operation. In addition, one patient in the control group had taken
47MATERIALS AND METHODS
dipyridamole. Before the elective operation, low-molecular-weight heparin was administered
to two patients in the algorithm group and one patient in the control group.
Study V
The purpose of Study V was to evaluate current transfusion practices in CABG opera-
tions at Helsinki University Central Hospital, utilizing the data stored automatically in
hospital registers. Comparisons were made with the retrospective data collected from
the same hospital from 1993 to 1994 (III). The transfusion data for consecutive
patients undergoing uncombined CABG at Helsinki University Central Hospital during
the 2.5-year period from 1997 to 1999 were collected. Since 1992, all transfusions in
this hospital have been recorded in a blood bank computer system (Vertti, WM-data
Consulting Oy, Vantaa, Finland). This transfusion register includes patient demograph-
ics, number of all blood component units transfused, and time of transfusion. In Study
V, this register was integrated with the patient administration system (Musti, Compaq
Computer Oy, Espoo, Finland and Novo Group Oy, Helsinki, Finland). SAS
programming tools were used for combining and grouping of the data (Base SAS, SAS
Institute Inc, Cary, NC, USA) to form a file containing information about surgical
procedures and related transfusions.
Statistical analyses
The results are presented as mean ± standard deviation or median, quartiles, and range.
A probability of less than 0.05 was considered significant.
In Studies I to III and V, Kruskal-Wallis one-way analysis of variance (ANOVA) was
used to detect interhospital or interperiod differences. In case of statistical significance
after ANOVA in Studies I and V, Dunn’s method was used to identify differences
between the groups. Proportions were compared with the χ2 test (I–III, V). Linear re-
gression analysis was used to test the influence of patients’ age on transfusion thresholds
in Study II. In Study IV, the Mann-Whitney U test was used to analyze the continuous
variables, and the frequencies were compared with Fisher’s exact test. The on-line and
conventional laboratory assays were compared with Spearman rank correlation (IV).
In Studies I and III, Poisson’s regression analysis was used to control the effect of diverse
patient groups on transfusion requirements. In Study I, the explanatory continuous
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variables were preoperative hematocrit, estimated blood volume, age, duration of
operation, and total blood loss, and the categorical variables used were hospital and
gender. The explanatory continuous variables in the Study III were preoperative hemo-
globin concentration and hematocrit, estimated initial RBC volume, age, CPB time,
and postoperative blood loss; categorical variables included hospital, gender, and pre-
operative aspirin exposure. Thus, the explanatory variables were those that differed
between centers and/or have been identified as determinants of blood component usage
in the previous literature concerning CABG operations (Cosgrove et al. 1985; Mago-
vern et al. 1996), or total joint replacements (Churchill et al. 1994; Nuttall et al.
1996).
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Transfusion practices in common elective surgical operations (I–III)
The main characteristics, blood loss, and hemoglobin concentrations of the patients in
four procedure groups studied are shown in Table 10.
Several variables with an effect on blood loss and transfusion requirements in total joint
replacements and CABG operations were studied between hospitals; in CABG, the
groups of patients in nine different hospitals were similar in respect to gender and pre-
operative RBC volume, whereas the age, CPB time, chest tube drainage, and proportion
of patients with ≤2 bypasses varied greatly between hospitals (see Table 1 in Study III).
In orthopedic operations, the age, weight and height of the THR patients differed between
the nine hospitals, whereas TKR patients were comparable in these respects. The mean
preoperative hemoglobin concentrations also varied significantly between hospitals
before these procedures. In both orthopedic procedures, the differences between hospitals in
the mean total blood loss and the mean duration of operation were approximately two-
fold (see Tables 1–3 in Study I). The effect of these confounding variables in trans-
fusions is analyzed in the chapter detailing results concerning the sources of variation in
transfusion practices. Orthopedic procedures were almost always performed under
regional anesthesia. None of the participating hospitals used hypotensive anesthesia.
Table 10. Patient characteristics, blood loss, and hemoglobin concentrations.
CABG THR TKR TURP
No. of hospitals 9 9 5 4
No. of patients (M/F) 653/151 309/455 93/304 343/–
Age, years 63 (55–69) 69 (63–75) 71 (66–73) 70 (65–75)
Weight, kg 79 (71–88) 75 (67–82) 75 (68–84) 78 (70–85)
Blood loss, ml
during surgery ND 800 (550–1100) ND ND
total 1000 (700–1350)a 1350 (1010–1830) 1200 (820–1700) ND
Hb, g/l
preoperative 144 (136–152) 139 (130–146) 136 (129–144) 143 (134–151)
last recorded 117 (109–126) 115 (108–122) 115 (108–120) 121 (111–136)b
Values are medians with 25 and 75 percentiles in parentheses.
Hb = hemoglobin concentration; ND = no data.
a Chest tube drainage.
b Hemoglobin concentration on the first postoperative morning.
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Allogeneic blood transfusions
RBCs. The allogeneic RBC transfusions in the four procedures are presented in Table
11. The transfusion rates in these operations varied from 18% in TURP operations to
92% in THR operations. However, significant differences appeared between hospitals in
all procedures regarding the rates of transfusion and in the units transfused per recipient
(Table 11, Figures 3 and 4).
Table 11. Allogeneic RBC transfusions during hospital stay.
Surgical Patients Range between Units per transfused patient, Variation between
procedure transfused, % hospitals, %a median (25–75 percentiles) hospitals, mediansb
CABG 87 53–99 3.0 (2.0–5.0) 2.0–5.0
THR 92 79–100 4.0 (2.0–5.0) 2.0–5.0
TKR 84 57–98 3.0 (2.0–4.0) 2.0–3.0
TURP 18 7–31 3.0 (2.0–3.0) 0
a Differences between hospitals at P<0.0001 (THR ,TKR and CABG), and P=0.0002 (TURP), χ2 test.
b Differences between hospitals at P<0.0001 (THR and CABG) and P<0.001 (TKR), ANOVA.
Figure 3. RBC transfusions in orthopedic operations.
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Hemostatic blood components. Platelets were administered to 68 (9%) of the CABG
patients, range 2 to 22% (P<0.001 between hospitals, χ2 test), the mean number of
units transfused was 8.3±3.6 (Figure 4). Preoperative platelet orders were made only in
hospitals 8 and 9, in which the platelet use was also greatest. One-fifth of the platelet
recipients were those who underwent re-exploration for bleeding. FFP was transfused to
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204 (25%) of the patients, range 5 to 49% (P<0.0001 between hospitals, χ2 test)
(Figure 4). The mean number of FFP units transfused per recipient was 2.8±1.9; four or
more units were transfused to 25% of the FFP recipients. For 45% of the recipients,
FFP had been set apart already before surgery. Resternotomy for bleeding was
performed on 29 (14%) of the FFP recipients. The mean chest tube drainage of patients
receiving any hemostatic blood component (n=220) was 1380±989 ml, and was
871±587 ml in those without FFP and/or platelet transfusions (P<0.001, Mann-Whitney U
test). In orthopedic operations, the use of platelets and FFP was minimal: platelets were
transfused to 5 and FFP to 31 orthopedic patients, respectively.
Figure 4. Number of blood component units transfused to an average patient at each hospital in CABG
operations (total number of RBC, FFP or platelet units transfused to all patients at each hospital divided
by number of patients).
Sources of variation in allogeneic blood usage
The variation between hospitals in transfusion requirements in orthopedics and cardiac
surgery was most significant, and at its widest in CABG operations (Figure 4). However,
the data may have been influenced by the differences in patient demographics and
operative variables. Regression analysis was used to control these differences, and
consequently to conclude whether transfusion policies between hospitals actually varied.
As described in detail in the methods section, the regression model predicted the
numbers of blood component units that would have been transfused to a patient
representing the average of all female (orthopedic operations) or male (CABG) patients
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in different hospitals. In total joint replacements and CABG operations, a marked
interhospital variation (from 2.4 to 4.1 RBC units per patient in THR, from 1.8 to 2.8
RBC units per patient in TKR, and from 1.1 to 6.1. blood component units per patient
in CABG) persisted after controlling for patient- and operation-related variables.
Consequently, the transfusion practices seemed to be strongly influenced by the hospital
itself instead of by the heterogeneity of the patient groups.
Transfusion thresholds
Blood loss in transfused patients. In Study II, the effect of blood loss on RBC transfusions in
orthopedic patients was evaluated by calculating the proportion of estimated total blood
volume (TBV) lost during hospitalization. The relationship of blood transfusions and
lost blood volume is shown in Figure 5. Most patients lost over 20% of their TBV, and
practically all of them received blood transfusions. Transfusions were also administered
to the majority of patients who lost 20% or less of their TBV.
Figure 5. Relationship between lost blood volume and RBC transfusion in THR and TKR patients.
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Laboratory data in transfused patients. In all four operations, hemoglobin thresholds
leading to RBC transfusion were evaluated by recording the lowest hemoglobin
concentrations in transfused patients intra- and postoperatively. Transfusion thresholds
in orthopedic operations and TURP are shown in Table 12, and thresholds in CABG in
Table 13. Decisions to transfuse hemostatic blood components in CABG patients were
usually made on the basis of clinical judgement; pre-transfusion platelet counts or
coagulation test results were mostly unobtainable from patient records.
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Table 12. Lowest postoperative hemoglobin concentrations (“transfusion thresholds”) in patients transfused
with RBCs during the postoperative period.
Surgical Patients transfused with Lowest postoperative Hb in Lowest and highest median
procedure RBCs postoperatively, % postoperatively transfused patients, thresholds observed among
g/l, median (25–75 percentiles) hospitals, g/l
THR 29 96 (90–101) 91–103
TKR 39 96 (90–101) 90–102
TURP 22 107 (100–112) 100–112
Hb = hemoglobin concentration.
Table 13. Lowest hemoglobin concentrations (“transfusion thresholds”) in CABG patients transfused with
RBCs during three periods.
  Period Patients transfused Lowest Hb in transfused Lowest and highest median
with RBCs, % patients, g/l thresholds observed among
median (25–75 percentiles) hospitals, g/l
During operation 46 79 (72–86) 65–86
After surgery until the first
postoperative morning 69 95 (88–102) 86–105
Postoperatively 39 98 (91–105) 90–111
Hb = hemoglobin concentration.
The use of blood conservation methods
In orthopedic operations, the use of blood conservation methods was practically limited
to reinfusion of postoperative drainage in 90 (23%) TKR patients (Table 4 in Study I).
In all, 22% of these patients received only autologous blood, whereas other patients
received additional allogeneic blood transfusions. No preoperative autologous blood
donation was arranged. Tranexamic acid was in experimental use in one hospital.
The use of autologous blood and hemostatic medications in CABG operations is
summarized in Table 3 in Study III. In all centers, crystalloid or colloid prime was used,
and remaining oxygenator contents were returned at the cessation of CPB. In all, intra-
operative salvage was the most widely used method to utilize autologous blood (32% of
the patients), followed by reinfusion of postoperative drainage (25%), and ANH (8%);
however, the use of these methods varied between hospitals. All hospitals except hospital
number 4 used either aprotinin or tranexamic acid in a varying share of their patients.
In all, tranexamic acid was used in 39% of the patients and aprotinin in 13%.
Combined blood conservation techniques, but not hemostatic agents, were used system-
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atically in hospital number 5. ANH, intraoperative salvage and reinfusion of shed
mediastinal blood were combined there in 55 of the 92 patients. However, only 9 (16%)
of these patients avoided exposure to allogeneic blood.
The effect of a treatment algorithm on hemostatic outcome and
transfusions in CABG (IV)
Study IV was designed to evaluate whether treatment of bleeding cardiac surgical
patients based on an algorithm with rapid on-site coagulation measurements would
improve their hemostatic outcome, and optimize the transfusion therapy in these
patients. In fact, algorithm-based therapy was shown to increase the utilization of
hemostatic interventions during the immediate recovery period (1 hour after surgery).
Significantly more patients received platelets (14 vs. 3 patients in the algorithm group
and control group respectively, P=0.0001, Fisher’s exact test) and DDAVP (8 vs. 2
patients in the algorithm group and control group, P=0.04, Fisher’s exact test) in the
algorithm group than in the control group in which the patients were managed solely
according to the clinician’s judgement and ACT measurements (Table 3 in Study IV).
However, these interventions did not affect the hemostatic outcome of these patients:
no difference was seen in blood loss (Figure 6) or transfusion requirements of any blood
components between the two treatment groups. The total number of blood donor
exposures was 17.2±17.2 in the algorithm group and 14.4±14.0 in the control group
(P=0.5, Mann-Whitney U test). The transfusion requirements of the treatment groups
are shown in detail in Table 4 in Study IV. The two groups were also similar in terms of
re-exploration rate and other outcome variables (Table 5 in Study IV).
Figure 6. Cumulative blood loss (mean ± standard deviation). Algorithm group with grey and control
group with black bars.
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Current transfusion practices in CABG operations in Helsinki
University Central Hospital (V)
Study V analyzed current large-scale transfusion data based on hospital registers in
Helsinki University Central Hospital. A great reduction in transfusion requirements in
2363 patients undergoing CABG was seen as compared to the results of Study III.
From 1993 to 1994, 76% of the CABG patients operated on received allogeneic blood
transfusions, whereas in the three six-month periods studied (1–6.1997, 1–6.1998 and
1–6.1999), the rates of allogeneic transfusion exposure were 68%, 52%, and 48%
respectively, P<0.01 between time-periods (χ2 test). The mean number of blood
component units transfused per CABG patient also decreased significantly (Figure 7).
These changes led to a marked reduction in transfusion costs: in 1997, the mean blood
product costs per patient were 179 Euro, and only 99 Euro in 1999. Automatically
stored hospital registers provided a good means for continuous evaluation and reporting
of transfusion practices.
Figure 7. Mean number of blood component units transfused per CABG patient in Helsinki University
Central hospital in 1993–1994 vs. 1997–1999. Significant reductions in the mean number of donor
exposures per patient in 1–6.1998 and 1–6.1999 as compared with 1–6.1997, P<0.05 (ANOVA).
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DISCUSSION
In Finland, the use of RBCs increased rapidly in the beginning of the 1990’s. Although
a plateau and slight decrease in use has occurred during the last few years, RBC use per
inhabitant in Finland is still among the highest in Europe. As a result of the
comparatively low risk of transfusion-transmitted viral infections in Finland, concern
about the safety of donor blood has remained modest both within both the medical
profession and the general public. This has probably had an influence on Finnish
transfusion policies. As the majority of RBC units are transfused in association with
surgery (Vamvakas and Taswell 1994), evaluation of the appropriateness of surgical
hemotherapy is of particular interest. The growth of RBC demand in Finland may be
explained in part by a simultaneous increase in the number of surgical procedures.
However, to examine the reasons for generous blood use per inhabitant, large-scale
comparative data on the rates of transfusion, and evaluation of the indications for blood
components used in elective surgical procedures were needed.
Rates of transfusion in elective surgical procedures
The allogeneic transfusion rates in total joint replacements and CABG operations in
Finnish hospitals were higher than in series from other European countries and the US
(Tables 4 and 5). In TURP, transfusion rates similar to ours have been reported
previously (Sirchia et al. 1994).
In primary total joint replacements in Finland from 1993 to 1994, the proportions of
patients receiving RBC transfusion were 92% in THR procedures and 84% in TKR.
Although the total blood losses in both surgical procedures were comparable with those
reported in the literature (Sirchia et al. 1994; Cushner and Friedman 1991), the
allogeneic transfusion rates in THR operations in large studies from the same time-
period ranged from 51% to 78% (Churchill et al. 1994; Sirchia et al. 1994; Pinkerton
1996; Pinkerton et al. 1998). In TKR, the difference was even greater: the proportion of
patients receiving allogeneic RBC transfusions in studies from Canada and the US was
approximately 30% (Churchill et al. 1994; Pinkerton et al. 1998). The mean numbers
of RBC units transfused per recipient in Study I, 3.9 units in THR and 3.1 units in
TKR, fell within the range reported from other countries. It is to be noted that in
studies using preoperative autologous blood donation, the total transfusion rates
(autologous and allogeneic), especially in THR operations, were quite similar to those in
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Study I (Churchill et al. 1994; Sirchia et al. 1994; Pinkerton et al. 1998). Consequently,
lower thresholds seem to be applied for transfusion of autologous than allogeneic blood. In
conclusion, although the amount of blood transfused per recipient was similar, the total
joint replacement patients were transfused more frequently in Finland than reported
elsewhere from 1993 to 1994.
In CABG operations, the overall allogeneic transfusion rate in all nine Finnish cardiac
centers from 1993 to 1994 was 88%. The proportions of patients receiving RBCs, FFP,
and platelets were 87%, 25%, and 9% respectively. From 1987 to 1988, a previous
countrywide study designed to determine the incidence of post-transfusion hepatitis in
Finland showed that the average blood component use was 12.3 units per CABG
(Ebeling et al. 1991). The corresponding figure in this study was 3.3 units. Although
the transfusion rates in CABG operations in Finland have obviously decreased rapidly,
lower RBC transfusion rates have frequently been reported from other countries (Table
5). The overall proportions of patients receiving hemostatic blood components in CABG
were comparable with those reported from abroad (Table 5). However, in some Finnish
centers, considerably large proportions of patients received FFP and platelet transfusions
(Figure 1 in Study III). In our survey, the mean estimated blood loss was similar to
those losses reported previously (Goodnough et al. 1991; Surgenor et al. 1992; Sirchia
et al. 1994).
The SANGUIS study conducted in the beginning of the 1990’s gives a good picture of
the transfusion practices in CABG operations in nine other European countries. In that
study, 73% of the patients received allogeneic RBC transfusions; however, the range
between hospitals was 17 to 100% (Sirchia et al. 1994). FFP and platelets were transfused
to 39% and 8% of the patients, respectively. Very low transfusion requirements have
been reported from some hospitals using multiple blood conservation methods. It was
unexpected to learn that in another Nordic country, in the Oslo Heart Center of
Norway, allogeneic blood transfusions are almost totally avoided (Øvrum et al. 1991).
All in all, although the allogeneic blood use in CABG operations in Finland compared
favorably with that in some European hospitals, the overall Finnish allogeneic RBC
transfusion rate was high.
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Thresholds for transfusion
RBCs
Based on the surgical and laboratory data, the thresholds for RBC transfusions applied
in Finnish hospitals were evaluated. Our results indicated that Finnish hospitals em-
ployed fairly conservative hemoglobin transfusion triggers. In all operations, the median
postoperative hemoglobin transfusion triggers, 96 g/l in total joint replacements, 107 g/l
in TURP, and 98 g/l in CABG, suggested that the traditional “10/30” rule was followed
(Adams and Lundy 1942; Lunn and Elwood 1970). During the CABG operation, the
median transfusion trigger hemoglobin 79 g/l (quartiles 72–86) was more in accordance
with the safety limits suggested for cardiac patients (Robertie and Gravlee 1990;
American Society of Anesthesiologists 1996). The median hemoglobin concentrations at
discharge, ranging between different surgical procedures from 115 g/l to 121 g/l (Table
10), were also high. Furthermore, when compared with the blood volume lost in total
joint replacements, the use of transfusions appeared excessive: most patients with a total
blood loss of 20% or less of their estimated total blood volume during the
hospitalization were transfused. According to proposed guidelines, at least the first 20%
of the blood loss in patients with normal initial hemoglobin concentrations can usually
be replaced with nonblood crystalloid and/or colloid solutions (Lundsgaard-Hansen
1980; Simon et al. 1998). Yet, the difficulty of estimating intraoperative blood loss
must be borne in mind when evaluating these results.
Moreover, the retrospective data available did not allow us to correlate the transfusion
thresholds with the patients’ clinical condition, anticipated blood loss, or comorbidities,
which have to be taken into consideration in RBC transfusion decisions. Still, based on
our survey, the blood loss in transfused patients, the hemoglobin thresholds during the
postoperative period, and the last recorded hemoglobin concentrations suggest that in
Finnish hospitals relative overtransfusion of RBCs occurred.
In the European SANGUIS study, the hematocrit thresholds for transfusion were lower
than those applied in Finnish hospitals. In CABG, THR, and TURP operations the
average pretransfusion hematocrits in the postoperative period were 28%, 26%, and
27%, respectively (Sirchia et al. 1994). In contrast, both 10-year-old and recent
questionnaire studies show that the “10/30”rule as well as transfusion for patients with
small bleeds has been and still is common practice in many hospitals (Stehling et al.
1987; Garrioch et al. 2000). In the survey of US anesthesiologists, 42% of the
practitioners answered that they would transfuse RBCs even prior to loss of 20% of the
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patient’s blood volume (Stehling et al. 1987). Although the use of hemoglobin
concentration as the sole trigger has repeatedly been rejected (American Society of
Anesthesiologists 1996; Simon et al. 1998), low hemoglobin concentration was shown
to be the main feature in transfusion decisions in Scotland in 1998, and hemoglobin
concentration 100 g/l the desired target for RBC transfusions (Garrioch et al. 2000).
Yet, as evidence as to the effect of different transfusion thresholds on patient outcome
based on observational or randomized studies is still scanty (Table 3), optimal RBC
transfusion practices in association with surgery are difficult to define. Available studies
suggest that RBC transfusion at a hemoglobin concentration from 80 to 100 g/l may
have no beneficial effect on patient outcome as measured by morbidity, mortality,
length of hospital stay, or patients’ self-assessment of their condition (Bush et al. 1997;
Carson et al. 1998a; Bracey et al. 1999). After cardiac surgery, high hematocrit values
may probably even be associated with poorer outcome and increased rate of
postoperative myocardial infarction (Spiess et al. 1998). On the other hand, extremely
restrictive indications for RBC transfusions have also raised concern about whether
strict blood conservation leads to undertransfusion (Mair et al. 1996).
Hemostatic components
The transfusion of FFP and platelets seemed to be empirically guided. In patients
receiving FFP and/or platelets, total blood loss was significantly greater than in those
not transfused with hemostatic components. Guidelines suggest that the transfusion of
FFP and platelets should generally be based on a verified coagulation defect or on lowered
platelet count, in addition to abnormal bleeding (Ciavarella et al. 1987; American
Society of Anesthesiologists 1996). However, in Finnish hospitals pre-transfusion coagu-
lation measurements and platelet counts were often not performed. One reason for this
practice surely was the lack of equipment to produce rapid bedside coagulation data at
that time. In the dynamic clinical situation, conventional laboratory assays are completed
too slowly. However, preoperative ordering of hemostatic blood components seemed to
be a clear determinant of subsequent transfusion: FFP and platelets were routinely set
apart before primary elective CABG operations in hospitals where transfusions were
commonly administered. Furthermore, in approximately 75% of the FFP recipients in
Study III, the dosage of FFP was insufficient to correct hemostasis, and the effect of FFP in
these patients may have been merely volume replacement. To be effective, the dose of
FFP should be great enough to raise the coagulation factor levels well above critical
levels (Braunstein and Oberman 1984; Woodman and Harker 1990). Usually this is
achieved with administration of 10 to 15 ml/kg of FFP.
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The use of blood conservation methods in Finnish hospitals
At the time of the survey, blood conservation methods were variably used in Finnish
hospitals. However, on the whole, autologous blood seemed to play a minor role in
Finnish transfusion practices. Predonations of autologous blood were and are organized
in our country only exceptionally by clinicians. Given the high degree of safety of allogeneic
blood, and the relatively rare applicability of preoperative donations, this seems to be a
prudent practice. In other countries, too, the use of preoperative autologous blood
donation is declining (Wallace et al. 1998).
According to our survey from 1993 to 1994, the use of hemostatic drugs and blood
salvage methods was most frequent in cardiac operations. In orthopedics, as appropriate
based on the moderate intraoperative blood losses (Goodnough et al. 1996), use of
autologous blood was limited mainly to reinfusion of postoperative drainage in TKR
operations. In CABG, tranexamic acid or aprotinin were used in varying proportions of
the patients in all except one cardiac center; however, the overall use of these agents was
minor. In all, intraoperative salvage was the most widely used method to utilize
autologous blood in cardiac surgery, followed by reinfusion of postoperative drainage,
and ANH; however, the use of these methods was again variable between hospitals.
Also, the blood conservation efforts in both cardiac and orthopedic surgery did not
reduce allogeneic blood transfusions to the degree reported in previous studies with
similar conservation methods (Øvrum et al. 1991; Gannon et al. 1991). This may be
explained by the higher transfusion thresholds applied in Finnish hospitals.
Overall use of both autologous blood and hemostatic agents, especially in cardiac
surgery, seems less in Finland than in other countries. This view is based on comparison
of Finnish practices with a recent survey of the use of blood conservation techniques in
association with cardiac and orthopedic surgery in nine countries (Fergusson et al.
1999). However, as the survey in Finland was conducted back in 1993 to 1994, the use
of blood conservation techniques may have gained popularity in Finland in recent years.
Furthermore, at the time of the survey, tranexamic acid was only in experimental use in
TKR operations in one hospital. Nowadays, the effectiveness of tranexamic acid in
reducing blood loss and transfusion requirements seems to be established (Hiippala et
al. 1997).
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Variation in transfusion practices between hospitals
According to our results, significant variation exists in the blood use between hospitals
in all surgical procedures studied (Table 11, Figures 3 and 4). This variation could be
only in part explained by the differences in demographic, laboratory, and surgical data.
However, marked interhospital variation in the mean number of units transfused per
patient, from 1.1 to 6.1 blood component units in CABG, from 2.4 to 4.1 RBC units
in THR, and from 1.8 to 2.8 RBC units in TKR, persisted after controlling for these
variables. Consequently, the probability of being transfused in equivalent surgical
procedures varied between Finnish hospitals as much as six-fold. Thus, it seems that
differences in local transfusion criteria, rather than heterogeneity of the patient groups
or differences in the apparent need for transfusion, may be the major source of this
variation. Our study confirms the results of previous multicenter studies of surgical
transfusion practices from Europe and the US (Goodnough et al. 1991; Sirchia et al.
1994; Hasley et al. 1995; Stover et al. 1998; Surgenor et al. 1998). In those studies, the
variability has been attributed to unnecessary transfusions, routine administration of
hemostatic components, and “the hospital effect”, which results from ingrained
institutional differences in training and hierarchical practices within the hospitals.
Those explanatory variables used to evaluate the role of the hospital itself in the
regression analyses in Studies I and III, were previously identified preoperative and
perioperative predictors of blood transfusion (Cosgrove et al. 1985; Churchill et al.
1994; Nuttall et al. 1996; Magovern et al. 1996). Postoperative chest tube drainage in
CABG operations and duration of surgery in THR operations, which differed consider-
ably between centers, were also included in the analysis. However, the effect of important
patient- and operation-related factors such as comorbidities, cardiac function, different
surgical approaches, and prosthesis fixation techniques were not analyzed (Mylod 1990;
Keene and Parker 1993; Magovern et al. 1996). If these variables had been taken into
account, differences between hospitals could have been narrowed. Nevertheless, wide
differences in transfusion practices between hospitals, especially in CABG operations,
could hardly be explained by the drawbacks in our study design.
A hospital’s teaching status did not seem to affect transfusion practices (Table 4 in
Study I). University hospitals were either moderate or generous blood users. These
observations are in agreement with those of previous studies (Friedman et al. 1980b;
Toy et al. 1992; Hasley et al. 1995).
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Little data exist on the influence of individual surgeons or anesthesiologists on trans-
fusion practices. The available studies are conflicting: individual surgeons have been
identified as independent determinants for blood transfusion (Dupuis et al. 1999), but,
on the other hand, transfusion practices have also been found to vary between centers
but be very uniform among surgeons practicing within one single hospital (Surgenor et
al. 1998). In our study, differences in local transfusion policies and specialist training
seemed to be reflected in CABG operations: in two cities in which CABG operations
are performed in private clinics in addition to university hospitals, the transfusion
practices in the hospitals situated in the same city were essentially identical, although
the practices between the cities differed.
The variation in transfusion practice places patients at variable risk of the adverse effects
of allogeneic blood transfusion, and may be a sign of inappropriate use of limited donor
blood resources. In addition, the variation in policies has a marked cost effect. In
Finnish hospitals, variation in blood product costs was at its widest in CABG operations, in
which the mean purchase costs of blood components transfused per patient varied
between hospitals over four-fold. When multiplied by the large number of cardiac and
orthopedic surgical procedures performed, this variation resulted in considerable
differences in annual blood component costs between centers.
An algorithm to guide transfusions in bleeding cardiac patients
Bedside measurements which provide coagulation data for analysis of the hemostatic
defects in bleeding surgical patients are now available for clinical use. In previous studies
in bleeding post-CPB cardiac surgical patients, transfusion algorithms guided by rapid
on-line hemostatic measurements have been suggested to be effective in reducing
allogeneic blood exposure (Despotis et al. 1994b; Shore-Lesserson et al. 1999). The
value of transfusion algorithms has been attributed to the fact that they effectively reach
the actual transfusion decision-makers at the time that they order the transfusions
(Despotis et al. 1994b).
As shown in Study III, the use of hemostatic components in association with CABG
was largely empirically guided, and in some Finnish hospitals generous. At the suggestion of
the clinicians in Helsinki University Central Hospital, a transfusion algorithm to guide
the administration of RBCs as well as hemostatic interventions in bleeding post-CPB
patients was designed and implemented. The control group represented purely empirical
therapy, which contrasts with the algorithms proposed previously (Despotis et al.
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1994b; Shore-Lesserson et al. 1999). Also, in contrast to a previous study using
subjective observation of the surgical field (Despotis et al. 1994b), we used an objective
measurement of blood loss to identify the patients with excessive bleeding after CPB.
The algorithm-based therapy seemed to increase the use of hemostatic interventions, as
defined by the use of platelet transfusions and DDAVP. However, these interventions
did not appear to lead to a better hemostatic outcome: blood loss, re-exploration rate
and allogeneic blood requirements were similar in the two treatment groups.
In our algorithm, we used for platelet transfusions a commonly suggested trigger,
platelet count <100 x 109/l (Goodnough et al. 1990; College of American Pathologists
1994; Despotis et al. 1994a). As platelet dysfunction is considered to be the leading
cause of bleeding after CPB, prompt correction of the platelet count was initiated after
verification of the heparin neutralization. However, no difference in hemostatic
outcome was detected between the two treatment approaches, the empirical and the
algorithm-based. On the other hand, no measurement of platelet function other than
bleeding time, which is thought to be a poor predictor of surgical bleeding (Lind 1991),
was included in the algorithm. As on-line tests of platelet function are being developed
and validated (Ereth et al. 1998; Shore-Lesserson et al. 1999), optimization of the
platelet transfusion therapy in post-CPB patients may be possible.
According to Study III, the study hospital was categorized as one of the three lowest
users of allogeneic blood. Consequently, the transfusion criteria in that hospital may be
considered more stringent than in most centers even before the introduction of the
algorithm. Thus, although use of the transfusion algorithm did not improve the study
hospital physicians’ transfusion practices, it might be an effective educational tool in
hospitals in which the intial allogeneic transfusion rate is high. Positive results of
previous studies encourage further development of transfusion algorithms.
Follow-up of transfusion practices
Compared to the time-consuming retrospective review, hospital information systems
seem to provide better means for evaluation of the transfusion practices (Hasley et al.
1995; Zimmermann et al. 1997; Pinkerton et al. 1998). Since Studies I to III, this
method of data collection has become available in some Finnish hospitals. In Study V,
the transfusion data routinely stored by the hospital’s blood bank were combined with
the register of the surgical procedures to form a file containing transfusion data on all
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CABG operations performed at Helsinki University Central Hospital during a 2.5-year
period from 1997 to 1999. This data-collection method enabled large-scale auditing of
the current transfusion practices associated with CABG operations in that one hospital.
In the hospital setting, this collection method can be used for continuous follow-up of
the transfusion practices in various surgical procedures.
As compared to the results of the survey from 1993 to 1994 (III), the allogeneic blood
use associated with CABG surgery at Helsinki University Central Hospital has decreased
from 76% to 48%. The mean number of donor exposures per patient fell from 3.3 units
to 2.0 units. A constant declining trend in the transfusion of all blood components was seen
also when the years 1997–1999 were compared with each other. The latter figures were
comparable with transfusion rates reported from elsewhere (Pinkerton et al. 1998;
Bjessmo and Ivert 2000).
Although the data-collection method made it possible to provide large-scale transfusion
statistics, it did not provide data concerning patient demographics, surgical variables,
blood loss, and laboratory measurements. Consequently, the thresholds leading to
transfusion decisions could not be evaluated. Although the availability and quality of
retrospective data is often poor (Sirchia et al. 1994; Audet et al. 1996), in our experi-
ence the data used in Studies I–III enabled, at least to some extent, the evaluation of the
transfusion triggers. Thus, to properly audit the transfusion decision-making at hospital
level, a database is needed that combines the transfusions given in various surgical
procedures with timed laboratory data, anesthesia records, and surgical variables.
The reasons for decreased allogeneic blood use in CABG procedures in one hospital
may be multifactorial. Although no association of the unmasked results of Studies III
and IV with decreased blood use has been proven, this may be considered a possibility.
Moreover, the transfusion algorithm may have prompted the individual clinicians to
revise their transfusion practices. Yet, the development of the surgical techniques and
the educational efforts made at hospital level may be of great importance. In Helsinki
University Central Hospital, the blood bank statistics on the blood usage and costs are
reported monthly to the clinical departments. In addition, a hospital transfusion
committee has formulated guidelines for blood component usage. Finally, the role of
physicians with a special interest in the field of surgical transfusion therapy working in
the hospital may have been crucial. As shown in previous studies, combined educational
efforts appear to be the key for improvement in transfusion practices (Barnette et al.
1990; Soumerai et al. 1993; Morrison et al. 1993; Brandis et al. 1994).
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The present study was undertaken to determine the transfusion practices in common
elective surgical procedures in Finnish hospitals, to identify areas that would need
improvement, and to seek methods to guide the transfusion practices.
In a large retrospective survey, the transfusion practices involving a total of 2308 patients
admitted for primary THR and TKR, first-time elective CABG, and TURP procedures
in 16 Finnish hospitals in 1993–1994 were studied. The overall RBC transfusion rates
in these procedures were 92% in THR, 84% in TKR, 87% in CABG, and 18% in TURP.
Although the blood losses in total joint replacements and CABG were comparable with
those reported from abroad, the RBC transfusion rates in these operations were higher
than in series from other European countries and the US. In TURP, transfusion rates
matched the results reported previously. The overall proportions of patients receiving FFP
and platelets, 25% and 9%, were comparable with those reported from other countries.
However, in some Finnish centers, considerably high rates of FFP and platelet trans-
fusion in CABG operations were detected. The use of blood conservation methods was
most frequent in cardiac operations, but did not reduce the use of allogeneic blood to
the degree reported from abroad.
As evaluated by the lost estimated blood volume, postoperative hemoglobin thresholds,
and the last recorded hemoglobin concentrations recorded during hospitalization in
transfused patients, RBC transfusions seemed to be readily administered in Finnish
hospitals. Most orthopedic patients with a total blood loss of 20% or less of their blood
volume were transfused with RBCs. In all operations, the median postoperative hemo-
globin transfusion triggers approximated 100 g/l, and the median last recorded hemo-
globin levels ranged from 115 g/l to 121 g/l among different surgical procedures. Based
on current knowledge of hemoglobin requirements in surgical patients, lower thresholds
for RBC transfusions might safely be applied.
The use of hemostatic blood components seemed to be empirically guided. Although
the use of hemostatic components in surgical patients should generally be based on
abnormal hemostatic data in addition to excessive bleeding, pre-transfusion hemostasis
measurements were generally not performed. This may have been due to the lack of
equipment to provide rapid on-line coagulation data at bedside. Consequently, very
diverse transfusion protocols in bleeding CABG patients were used in Finnish hospitals.
Furthermore, the dosage in most FFP recipients seemed to be insufficient.
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On the basis of the results of Studies I and III, transfusion practices seemed to be highly
variable between Finnish hospitals. This variation could only in part be explained by the
differences in the patient populations in the Finnish hospitals. After controlling for
these factors, the probability of being transfused in equivalent surgical procedures varied
among Finnish hospitals as much as six-fold. Thus, it seems that transfusion practices
were largely determined by local transfusion criteria.
To guide transfusion decisions in bleeding post-CPB patients, a transfusion algorithm
with rapid on-line coagulation data was designed and implemented in Helsinki University
Central Hospital. However, as compared to the therapy based on the clinician’s discretion,
the algorithm-guided therapy increased the use of hemostatic interventions, without
any obvious benefit to hemostatic outcome. In the study hospital, transfusion practices
followed fairly well the international guidelines even before the introduction of the
algorithm. In other studies, algorithm-based transfusion has reduced the use of blood
components, and it may be suggested that an algorithm could be an effective educational
tool in hospitals in which the initial transfusion rate is high. Further development of
transfusion algorithms is warranted.
The data automatically stored in the hospital registers provide a good means for continuous
follow-up of the transfusion practices associated with surgical procedures. In Study V, the
transfusion data provided by the Helsinki University Central Hospital’s blood bank were
combined with the hospital’s register of CABG procedures from 1997 to 1999. As compared
to the results of the survey from 1993 to 1994 (III), the allogeneic blood-use data associated
with this procedure has decreased to the level reported from other countries. In Study III,
the allogeneic transfusion rate in this hospital was 76%, whereas in Study V, the transfusion
rate in 2363 CABG patients from 1997 to 1999 was 48%. A constant trend toward a
decline in the transfusion of all blood components was seen also during the years 1997 to
1999. The reasons for these changes may be multifactorial and related to educational efforts
made by the hospital’s blood bank, to special interest in the surgical transfusion practices at
hospital level, and to development of surgical techniques. However, the previous studies (III
and IV) may also have contributed to revision of the indications for blood transfusion.
In this study, the transfusion practices in elective surgery in Finnish hospitals were
examined by use of methods available at that time. These results cover only a part of the
surgical blood use and give some explanations for the relatively generous use of RBCs in
Finland. In the future, the improving information systems at hospital level and in the
blood transfusion services hopefully will enable linking of all blood units with the
recipient, and also provide appropriate patient- and procedure-related data. These
methods may facilitate optimization of blood use.
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